Cervarix

1 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

ANNEX I 
 

SUMMARY OF PRODUCT CHARACTERISTICS 



2 

 
1. NAME OF THE MEDICINAL PRODUCT 
  
Cervarix suspension for injection in pre-filled syringe 
Cervarix suspension for injection in a vial 
Cervarix suspension for injection in multidose container 
 
Human Papillomavirus vaccine [Types 16, 18] (Recombinant, adjuvanted, adsorbed) 
 
 
2. QUALITATIVE AND QUANTITATIVE COMPOSITION  
 
1 dose (0.5 ml) contains: 
 
Human Papillomavirus1 type 16 L1 protein2,3,4 20 micrograms 
Human Papillomavirus1 type 18 L1 protein2,3,4 20 micrograms 
 
1Human Papillomavirus = HPV 
 
2adjuvanted by AS04 containing: 
3-O-desacyl-4’- monophosphoryl lipid A (MPL)3 50 micrograms 
 
3adsorbed on aluminium hydroxide, hydrated (Al(OH)3)  0.5 milligrams Al3+ in total 
 
4L1 protein in the form of non-infectious virus-like particles (VLPs) produced by recombinant DNA 

technology using a Baculovirus expression system which uses Hi-5 Rix4446 cells derived from 
Trichoplusia ni. 

 
For the full list of excipients, see section 6.1. 
 
 
3. PHARMACEUTICAL FORM 
 
Suspension for injection. 
Turbid white suspension.  
 
 
4.  CLINICAL PARTICULARS 
 
4.1 Therapeutic indications 
 
Cervarix is a vaccine for use from the age of 9 years for the prevention of premalignant ano-genital 
lesions (cervical, vulvar, vaginal and anal) and cervical and anal cancers causally related to certain 
oncogenic Human Papillomavirus (HPV) types. See sections 4.4 and 5.1 for important information on 
the data that support this indication.  
 
The use of Cervarix should be in accordance with official recommendations. 
 
4.2 Posology and method of administration 
 
Posology 
 
The vaccination schedule depends on the age of the subject. 
 



3 

Age at the time of the first 
injection Immunization and schedule 

9 to and including 14 years* Two doses each of 0.5 ml. The second dose given between 5 and 13 months after the first dose 

From 15 years and above Three doses each of 0.5 ml at 0, 1, 6 months** 

*If the second vaccine dose is administered before the 5th month after the first dose, a third dose 
should always be administered. 
**If flexibility in the vaccination schedule is necessary, the second dose can be administered between 
1 month and 2.5 months after the first dose and the third dose between 5 and 12 months after the first 
dose.  
 
The need for a booster dose has not been established (see section 5.1). 
 
It is recommended that subjects who receive a first dose of Cervarix complete the vaccination course 
with Cervarix (see section 4.4). 
 
Paediatric population (children < 9 years of age) 
 
Cervarix is not recommended for use in children below 9 years of age due to limited data on safety 
and immunogenicity in this age-group. 
 
Method of administration 
 
Cervarix is for intramuscular injection in the deltoid region (see also sections 4.4 and 4.5). 
 
Cervarix should under no circumstances be administered intravascularly or intradermally. No data are 
available on subcutaneous administration of Cervarix (see section 4.4). 
 
If Cervarix is to be given at the same time as another injectable vaccine, the vaccines should always be 
administered at different injection sites (see section 4.5). 
 
4.3 Contraindications 
 
Hypersensitivity to the active substances or to any of the excipients listed in section 6.1. 
 
4.4 Special warnings and precautions for use 
 
As with all injectable vaccines, appropriate medical treatment and supervision should always be 
readily available in case of a rare anaphylactic reaction following the administration of the vaccine. 
 
Syncope (fainting) can occur following, or even before, any vaccination especially in adolescents as 
a psychogenic response to the needle injection. This can be accompanied by several neurological 
signs such as transient visual disturbance, paraesthesia and tonic-clonic limb movements during 
recovery. It is important that procedures are in place to avoid injury from faints. 
 
Administration of Cervarix should be postponed in subjects suffering from an acute severe febrile 
illness. However, the presence of a minor infection, such as a cold, is not a contraindication for 
immunisation. 
 
The vaccine should under no circumstances be administered intravascularly or intradermally.  
No data are available on subcutaneous administration of Cervarix. 



4 

 
As with other vaccines administered intramuscularly, Cervarix should be given with caution to 
individuals with thrombocytopenia or any coagulation disorder since bleeding may occur following an 
intramuscular administration to these subjects.  
 
As with any vaccine, a protective immune response may not be elicited in all vaccinees.  
 
Cervarix will only protect against diseases that are caused by HPV types 16 and 18 and to some extent 
against diseases caused by certain other oncogenic related HPV types (see section 5.1). Therefore, 
appropriate precautions against sexually transmitted diseases should continue to be used.  
 
The vaccine is for prophylactic use only and has no effect on active HPV infections or established 
clinical disease. The vaccine has not been shown to have a therapeutic effect. The vaccine is therefore 
not indicated for treatment of cervical cancer or cervical intraepithelial neoplasia (CIN).  It is also not 
intended to prevent progression of other established HPV-related lesions or existing HPV infections 
with vaccine or non-vaccine types (see section 5.1 “Efficacy against HPV-16/18 in women with 
evidence of HPV-16 or HPV-18 infection at study entry.”). 
 
Vaccination is not a substitute for routine cervical screening. Since no vaccine is 100% effective and 
Cervarix will not provide protection against every HPV type, or against existing HPV infections, 
routine cervical screening remains critically important and should follow local recommendations. 
 
Duration of protection has not fully been established. Timing and need of booster dose(s) has not been 
established. 
 
Except for asymptomatic human immunodeficiency virus (HIV) infected subjects for whom 
immunogenicity data are available (see section 5.1), there are no data on the use of Cervarix in 
subjects with impaired immune responsiveness such as patients receiving immunosuppressive 
treatment. As with other vaccines, an adequate immune response may not be elicited in these 
individuals. 
 
There are no safety, immunogenicity or efficacy data to support interchangeability of Cervarix with 
other HPV vaccines. 
 
Traceability 
In order to improve the traceability of biological medicinal products, the name and the batch number 
of the administered product should be clearly recorded. 
 
4.5 Interaction with other medicinal products and other forms of interaction 
 
In all clinical trials individuals who had received immunoglobulin or blood-derived products within 3 
months prior to the first vaccine dose were excluded. 
 
Use with other vaccines 
 
Cervarix may be administered concomitantly with a combined booster vaccine containing diphtheria 
(d), tetanus (T) and pertussis [acellular] (pa) with or without inactivated poliomyelitis (IPV), (dTpa, 
dTpa-IPV vaccines), with no clinically relevant interference with antibody response to any of the 
components of either vaccine. The sequential administration of combined dTpa-IPV followed by 
Cervarix one month later tended to elicit lower anti-HPV-16 and anti-HPV-18 GMTs as compared to 
Cervarix alone. The clinical relevance of this observation is not known. 
Cervarix may also be administered concomitantly with meningococcal serogroups A, C, W-135, Y 
tetanus toxoid conjugate vaccine (MenACWY-TT); with combined hepatitis A (inactivated) and 
hepatitis B (rDNA) vaccine (Twinrix) or with hepatitis B (rDNA) vaccine (Engerix B). 
Administration of Cervarix at the same time as Twinrix has shown no clinically relevant interference 
in the antibody response to the HPV and hepatitis A antigens. Anti-HBs geometric mean antibody 
concentrations were significantly lower on co-administration, but the clinical relevance of this 



5 

observation is not known since the seroprotection rates remain unaffected. The proportion of subjects 
reaching anti-HBs ≥ 10mIU/ml was 98.3% for concomitant vaccination and 100% for Twinrix given 
alone. Similar results were observed when Cervarix was given concomitantly with Engerix B with 
97.9% of subjects reaching anti-HBs ≥ 10mIU/ml compared to 100% for Engerix B given alone. 
 
If Cervarix is to be given at the same time as another injectable vaccine, the vaccines should always be 
administered at different injection sites. 
 
Use with hormonal contraceptive 
 
In clinical studies, approximately 60% of women who received Cervarix used hormonal 
contraceptives. There is no evidence that the use of hormonal contraceptives has an impact on the 
efficacy of Cervarix. 
 
Use with systemic immunosuppressive medicinal products 
 
See section 4.4. 
 
4.6 Fertility, pregnancy and lactation 
 
Pregnancy 
 
Specific studies of the vaccine in pregnant women were not conducted. Data in pregnant women 
collected as part of pregnancy registries, epidemiological studies and inadvertent exposure during 
clinical trials are insufficient to conclude whether or not vaccination with Cervarix affects the risk of 
adverse pregnancy outcomes including spontaneous abortion. 
However, during the clinical development program, a total of 10,476 pregnancies were reported 
including 5,387 in women who had received Cervarix. Overall, the proportions of pregnant subjects 
who experienced specific outcomes (e.g., normal infant, abnormal infants including congenital 
anomalies, premature birth, and spontaneous abortion) were similar between treatment groups.  
 
Animal studies do not indicate direct or indirect harmful effects with respect to fertility, pregnancy, 
embryonal/foetal development, parturition or post-natal development (see section 5.3). 
 
As a precautionary measure, it is preferable to avoid the use of Cervarix during pregnancy. Women 
who are pregnant or trying to become pregnant, are advised to postpone or interrupt vaccination until 
completion of pregnancy. 
 
Breast-feeding 
 
The effect on breast-fed infants of the administration of Cervarix to their mothers has not been 
evaluated in clinical studies. 
 
Cervarix should only be used during breast-feeding when the possible advantages outweigh the 
possible risks. 
 
Fertility 
 
No fertility data are available. 
 
4.7 Effects on ability to drive and use machines 
 
No studies on the effects on the ability to drive or use machines have been performed. However, some 
of the effects mentioned under section 4.8 “Undesirable effects” may temporarily affect the ability to 
drive or use machines. 
 
4.8 Undesirable effects 



6 

 
Summary of the safety profile 
 
In clinical studies that enrolled girls and women aged from 10 up to 72 years (of which 79.2% were 
aged 10-25 years at the time of enrolment), Cervarix was administered to 16,142 females whilst 
13,811 females received control. These subjects were followed for serious adverse events over the 
entire study period. In a pre-defined subset of subjects (Cervarix = 8,130 versus control = 5,786), 
adverse events were followed for 30 days after each injection. In two clinical studies that enrolled 
males aged 10 to 18 years, 2,617 males received Cervarix and were followed-up with active safety 
surveillance.  
 
The most common adverse reaction observed after vaccine administration was injection site pain 
which occurred after 78% of all doses. The majority of these reactions were of mild to moderate 
severity and were not long lasting. 
 
Tabulated list of adverse reactions 
 
Adverse reactions considered as being at least possibly related to vaccination have been categorised 
by frequency. 
 
Frequencies are reported as: 
Very common (≥1/10) 
Common (≥1/100 to <1/10) 
Uncommon (≥1/1,000 to <1/100) 
 
System Organ Class Frequency Adverse reactions 
Clinical trials 
Infections and infestations Uncommon Upper respiratory tract infection 
Nervous system disorders 
 

Very common Headache 
Uncommon Dizziness 

Gastrointestinal disorders Common Gastrointestinal symptoms including nausea, 
vomiting, diarrhoea and abdominal pain  

Skin and subcutaneous tissue 
disorders 

Common Itching/pruritus, rash, urticaria 

Musculoskeletal and connective 
tissue disorders 

Very common Myalgia 
Common Arthralgia 

General disorders and 
administration site conditions 
 

Very common Injection site reactions including pain, redness, 
swelling, fatigue 

Common Fever (≥38°C) 
Uncommon Other injection site reactions such as induration, 

local paraesthesia 
Post-marketing experience 
Blood and lymphatic system 
disorders 

Not known* Lymphadenopathy 

Immune system disorders Not known* Allergic reactions (including anaphylactic and 
anaphylactoid reactions), angioedema 

Nervous system disorders Not known* Syncope or vasovagal responses to injection, 
sometimes accompanied by tonic-clonic 
movements (see section 4.4) 

*Because these events were reported spontaneously, it is not possible to reliably estimate their 
frequency 

 
In clinical trials a similar safety profile has been observed in subjects with prior or current HPV 
infection as compared to subjects negative for oncogenic HPV DNA or seronegative for HPV-16 and 
HPV-18 antibodies. 
 



7 

Reporting of suspected adverse reactions 
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It 
allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare 
professionals are asked to report any suspected adverse reactions via the national reporting system 
listed in Appendix V. 
 
4.9 Overdose 
 
No case of overdose has been reported. 
 
 
5.  PHARMACOLOGICAL PROPERTIES 
 
5.1 Pharmacodynamic properties 
 
Pharmacotherapeutic group: Vaccines, Papillomavirus vaccines, ATC code: J07BM02 
 
Mechanism of action 
 
Cervarix is an adjuvanted non-infectious recombinant vaccine prepared from the highly purified virus-
like particles (VLPs) of the major capsid L1 protein of oncogenic HPV types 16 and 18. Since the 
VLPs contain no viral DNA, they cannot infect cells, reproduce or cause disease. Animal studies have 
shown that the efficacy of L1 VLP vaccines is largely mediated by the development of a humoral 
immune response. 
 
HPV-16 and HPV-18 are estimated to be responsible for approximately 70% of cervical cancers, 90% 
of anal cancers, 70% of HPV-related high grade vulvar and vaginal intraepithelial neoplasia and 78% 
of HPV related high-grade anal (AIN 2/3) intraepithelial neoplasia. 
Other oncogenic HPV types can also cause ano-genital cancers (approximately 30%). HPV 45, -31 
and -33 are the 3 most common non-vaccine HPV types identified in squamous cervical carcinoma 
(12.1%) and adenocarcinoma (8.5%). 
 
The term “premalignant ano-genital lesions” in section 4.1 corresponds to high-grade Cervical 
Intraepithelial Neoplasia (CIN2/3), high-grade vulvar intraepithelial neoplasia (VIN2/3), high-grade 
vaginal intraepithelial neoplasia (VaIN2/3) and high-grade anal intraepithelial neoplasia (AIN 2/3). 
 
Clinical studies 
 
Clinical efficacy in women aged 15 to 25 years 
 
The efficacy of Cervarix was assessed in two controlled, double-blind, randomised Phase II and III 
clinical trials that included a total of 19,778 women aged 15 to 25 years. 
 
The phase II trial (study 001/007) enrolled only women who: 
- Were tested negative for oncogenic HPV DNA of types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 

58, 59, 66 and 68 
- Were seronegative for HPV-16 and HPV-18 and  
- Had normal cytology 
The primary efficacy endpoint was incident infection with HPV-16 and/or HPV-18. Twelve-month 
persistent infection was evaluated as additional efficacy endpoint. 
 
The phase III trial (study 008) enrolled women without pre-screening for the presence of HPV 
infection, i.e. regardless of baseline cytology and HPV serological and DNA status. 
The primary efficacy endpoint was CIN2+ associated with HPV-16 and/or HPV-18 (HPV-16/18). 
Cervical Intraepithelial Neoplasia (CIN) grade 2 and 3 (CIN2/3) and cervical adenocarcinoma in situ 
(AIS) were used in the clinical trials as surrogate markers for cervical cancer. 
The secondary endpoints included 6- and 12-month persistent infection. 

http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc
http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc


8 

 
Persistent infection that lasts for at least 6 months has also been shown to be a relevant surrogate 
marker for cervical cancer in women aged 15 to 25 years. 
 
Prophylactic efficacy against HPV-16/18 infection in a population naïve to oncogenic HPV types  
 
Women (N=1,113) were vaccinated in study 001 and evaluated for efficacy up to month 27. A subset 
of women (N=776) vaccinated in study 001 was followed in study 007 up to 6.4 years (approximately 
77 months) after the first dose (mean follow-up of 5.9 years). There were five cases of 12-month 
persistent HPV-16/18 infection (4 HPV-16; 1 HPV-18) in the control group and one HPV-16 case in 
the vaccine group in study 001. In study 007 the efficacy of Cervarix against 12-month persistent 
HPV-16/18 infection was 100% (95% CI: 80.5; 100). There were sixteen cases of persistent HPV-16 
infection, and five cases of persistent HPV-18 infection, all in the control group. 
 
In study HPV-023, subjects from the Brazilian cohort (N=437) of study 001/007 were followed up to a 
mean of 8.9 years (standard deviation 0.4 years) after the first dose. At study completion, there were 
no cases of infection or histopathological lesions associated with HPV-16 or HPV-18 in the vaccine 
group in study HPV-023.  In the placebo group, there were 4 cases of 6-month persistent infection and 
1 case of 12-month persistent infection. The study was not powered to demonstrate a difference 
between the vaccine and the placebo group for these endpoints. 
 
Prophylactic efficacy against HPV-16/18 in women naïve to HPV-16 and/or HPV-18 
 
In study HPV-008, the primary analyses of efficacy were performed on the According to Protocol 
cohort (ATP cohort: including women who received 3 vaccine doses and were DNA negative and 
seronegative at month 0 and DNA negative at month 6 for the HPV type considered in the analysis). 
This cohort included women with normal or low-grade cytology at baseline and excluded only women 
with high-grade cytology (0.5% of the total population). Case counting for the ATP cohort started on 
day 1 after the third dose of vaccine. 
 
Overall, 74% of women enrolled were naïve to both HPV-16 and HPV-18 (i.e. DNA negative and 
seronegative at study entry). 
Two analyses of study HPV-008 have been performed: an event-triggered analysis performed once at 
least 36 CIN2+ cases associated with HPV-16/18 were accrued in the ATP cohort and an end-of study 
analysis. 
 
Vaccine efficacy against the primary endpoint CIN2+at the end of study is presented in Table 1. In a 
supplemental analysis, the efficacy of Cervarix was evaluated against HPV-16/18-related CIN3+. 
 
Table 1: Vaccine efficacy against high grade cervical lesions associated with HPV-16/18 (ATP 
cohort)  

HPV-16/18 endpoint ATP cohort(1) 
End of study analysis(3) 

Cervarix 
(N = 7,338) 

Control 
(N = 7,305) 

% Efficacy (95% CI) 

n(2) n 
CIN2+ 5 97 94.9% (87.7;98.4) 
CIN3+ 2 24 91.7% (66.6;99.1) 
N = number of subjects included in each group 
n = number of cases 
(1) ATP: includes women who received 3 doses of vaccine, were DNA negative and seronegative at 
month 0 and DNA negative at month 6 to the relevant HPV type (HPV-16 or HPV-18)  
(2) including 4 cases of CIN2+ and 2 cases of CIN3+ in which another oncogenic HPV type was 

identified in the lesion, concomitantly with HPV-16 or HPV-18. These cases are excluded in the 
HPV type assignment analysis (see under Table). 

(3) mean follow-up of 40 months post dose 3 
 



9 

At the event-triggered analysis the efficacy was 92.9% (96.1% CI: 79.9;98.3) against CIN2+ and 80% 
(96.1% CI: 0.3;98.1) against CIN3+. In addition, statistically significant vaccine efficacy against 
CIN2+ associated with HPV-16 and HPV-18 individually was demonstrated. 
 
Further investigation of the cases with multiple HPV types considered the HPV types detected by 
Polymerase Chain Reaction (PCR) in at least one of the two preceding cytology samples, in addition 
to types detected in the lesion to distinguish the HPV type(s) most likely responsible to the lesion 
(HPV type assignment). This post-hoc analysis excluded cases (in the vaccine group and in the control 
group) which were not considered to be causally associated with HPV-16 or HPV-18 infections 
acquired during the trial. 
Based on the HPV type assignment post-hoc analysis, there was 1 CIN2+ case in the vaccine group 
versus 92 cases in the control group (Efficacy 98.9% (95% CI: 93.8;100)) and no CIN3+ case in the 
vaccine group versus 22 cases in the control group (Efficacy 100% (95% CI: 81.8;100)) at the end of 
study analysis. 
 
In the event-triggered analysis, vaccine efficacy against CIN1 associated with HPV 16/18 observed in 
the ATP cohort was 94.1% (96.1% CI: 83.4;98.5).  Vaccine efficacy against CIN1+ associated with 
HPV 16/18 observed in the ATP cohort was 91.7% (96.1% CI: 82.4;96.7).  At the end of study 
analysis, vaccine efficacy against CIN1 associated with HPV 16/18 observed in the ATP cohort was 
92.8% (95% CI: 87.1;96.4). 
 
At end of study analysis, there were 2 cases of VIN2+ or VaIN2+ in the vaccine group and 7 cases in 
the control group in the ATP cohort associated with HPV-16 or HPV-18.  The study was not powered 
to demonstrate a difference between the vaccine and the control group for these endpoints. 
 
Vaccine efficacy against virological endpoints (6-month and 12-month persistent infection) associated 
with HPV-16/18 observed in the ATP cohort at the end of study is presented in Table 2. 
 
Table 2: Vaccine efficacy against virological endpoints associated with HPV-16/18 (ATP cohort)  

HPV-16/18 endpoint ATP cohort(1) 
End of study analysis(2) 

Cervarix 
(N = 7,338) 

Control 
(N = 7,305) 

% Efficacy 
(95% CI) 

n/N n/N 
6-month persistent 
infection 

35/7,182 588/7,137 94.3% 
(92.0;96.1) 

12-month persistent 
infection 

26/7,082 354/7,038 92.9% 
(89.4;95.4) 

N = number of subjects included in each group 
n = number of cases 
(1) ATP: includes women who received 3 doses of vaccine, were DNA negative and 

seronegative at month 0 and DNA negative at month 6 to the relevant HPV type (HPV-
16 or HPV-18) 

(2) mean follow-up of 40 months post dose 3 
 
The efficacy results at the event-triggered analysis were 94.3% (96.1% CI: 91.5;96.3) against 6-month 
persistent infection and 91.4% (96.1% CI: 89.4;95.4) against 12-month persistent infection. 
 
Efficacy against HPV-16/18 in women with evidence of HPV-16 or HPV-18 infection at study entry. 
 
There was no evidence of protection from disease caused by the HPV types for which subjects were 
HPV DNA positive at study entry. However, individuals already infected (HPV DNA positive) with 
one of the vaccine-related HPV types prior to vaccination were protected from clinical disease caused 
by the other vaccine HPV type. 
 
Efficacy against HPV types 16 and 18 in women with and without prior infection or disease. 
 



10 

The Total Vaccinated Cohort (TVC) included all subjects who received at least one dose of the 
vaccine, irrespective of their HPV DNA status, cytology and serostatus at baseline. This cohort 
included women with or without current and/or prior HPV infection. Case counting for the TVC 
started on day 1 after the first dose. 
The efficacy estimates are lower in the TVC as this cohort includes women with pre-existing 
infections/lesions, which are not expected to be impacted by Cervarix. 
The TVC may approximate to the general population of women in the age range of 15-25 years. 
 
Vaccine efficacy against high grade cervical lesions associated with HPV-16/18 observed in TVC at 
end of study is presented in Table 3. 
 
Table 3: Vaccine efficacy against high grade cervical lesions associated with HPV-16/18 (TVC)  

HPV-
16/18 

endpoint 

TVC(1) 
End of study analysis(2) 

Cervarix 
(N = 8,694) 

Control 
(N = 8,708) 

% Efficacy (95% CI) 

n n 
CIN2+ 90 228 60.7% (49.6;69.5) 
CIN3+ 51 94 45.7% (22.9;62.2) 
N = number of subjects included in each group 
n = number of cases 
(1) TVC: includes all vaccinated subjects (who received at least one dose of vaccine) irrespective of 

HPV DNA status, cytology and serostatus at baseline. This cohort includes women with pre-
existing infections/lesions 

(2) mean follow-up of 44 months post dose 1 
 
Vaccine efficacy against virological endpoints (6-month and 12-month persistent infection) associated 
with HPV-16/18 observed in TVC at end of study is presented in Table 4. 
 
Table 4: Vaccine efficacy against virological endpoints associated with HPV-16/18 (TVC)  

HPV-16/18 
endpoint 

TVC(1) 
End of study analysis(2) 

Cervarix 
 

Control 
 

% Efficacy (95% CI) 

n/N n/N 
6-month persistent 
infection 

504/8,863 1,227/8,870 60.9% (56.6;64.8) 

12-month persistent 
infection 

335/8,648 767/8,671 57.5% (51.7;62.8) 

N = number of subjects included in each group 
n = number of cases 
(1) TVC: includes all vaccinated subjects (who received at least one dose of vaccine) irrespective of 

HPV DNA status, cytology and serostatus at baseline. 
(2) mean follow-up of 44 months post dose 1 

 
Overall impact of the vaccine on cervical HPV disease burden 
 
In study HPV-008, the incidence of high grade cervical lesions was compared between the placebo 
and vaccine group irrespective of the HPV DNA type in the lesion. In the TVC and TVC-naïve 
cohorts, the vaccine’s efficacy was demonstrated against high-grade cervical lesions at end of study 
(Table 5). 
The TVC-naïve is a subset of the TVC that includes women with normal cytology, and who were HPV 
DNA negative for 14 oncogenic HPV types and seronegative for HPV-16 and HPV-18 at baseline. 
 
 
 



11 

 
Table 5: Vaccine efficacy against high-grade cervical lesions irrespective of the HPV DNA type in 
the lesion 
 End of study analysis(3) 

Cervarix Control % Efficacy (95% CI) 
N Cases N Cases 

CIN2+ 
TVC-naïve(1) 5,466 61 5,452 172 64.9% (52.7;74.2) 
TVC(2) 8,694 287 8,708 428 33.1% (22.2;42.6) 
CIN3+ 
TVC-naïve(1) 5,466 3 5,452 44 93.2% (78.9;98.7) 
TVC(2) 8,694 86 8,708 158 45.6% (28.8;58.7) 
N = number of subjects included in each group 
(1) TVC naïve: includes all vaccinated subjects (who received at least one dose of 

vaccine) who had normal cytology, were HPV DNA negative for 14 oncogenic 
HPV types and seronegative for HPV-16 and HPV-18 at baseline.  

(2) TVC: includes all vaccinated subjects (who received at least one dose of vaccine) 
irrespective of HPV DNA status, cytology and serostatus at baseline. 

(3) mean follow-up of 44 months post dose 1 
 
At the end of study analysis, Cervarix reduced definitive cervical therapy procedures (includes loop 
electrosurgical excision procedure [LEEP], cold-knife Cone, and laser procedures) by 70.2% (95% CI: 
57.8;79.3) in TVC-naïve and 33.2% (95% CI: 20.8;43.7) in TVC. 
 
Cross-protective efficacy 
 
The cross-protective efficacy of Cervarix against histopathological and virological endpoints 
(persistent infection) has been evaluated in study HPV-008 for 12 non-vaccine oncogenic HPV types. 
The study was not powered to assess efficacy against disease caused by individual HPV types.  The 
analysis against the primary endpoint was confounded by multiple co-infections in the CIN2+ lesions.  
Unlike histopathological endpoints, virological endpoints are less confounded by multiple infections. 
 
HPV-31, 33 and 45 showed consistent cross-protection for 6-month persistent infection and CIN2+ 
endpoints in all study cohorts. 
 
End of study vaccine efficacy against 6-month persistent infection and CIN2+ associated with 
individual non-vaccine oncogenic HPV types is presented in Table 6 (ATP cohort). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 



12 

 
Table 6: Vaccine efficacy for non-vaccine oncogenic HPV types 

ATP(1) 
HPV type 6-month persistent infection CIN2+ 

Cervarix Control % Efficacy 
(95% CI) 

Cervarix Control % Efficacy  
(95% CI) n n n n 

HPV-16 related types (A9 species) 
HPV-31 58 247 76.8%  

(69.0;82.9) 
5 40 87.5% 

(68.3;96.1) 
HPV-33 65 117 44.8%  

(24.6;59.9) 
13 41 68.3%  

(39.7;84.4) 
HPV-35 67 56 -19.8% 

(<0.0;17.2) 
3 8 62.5%  

(<0.0;93.6) 
HPV-52 346 374 8.3% 

(<0.0;21.0) 
24 33 27.6% 

(<0.0;59.1) 
HPV-58 144 122 -18.3% 

(<0.0;7.7) 
15 21 28.5% 

(<0.0;65.7) 
HPV-18 related types (A7 species) 
HPV-39 175 184 4.8% 

(<0.0;23.1) 
4 16 74.9%  

(22.3;93.9) 
HPV-45 24 90 73.6%  

(58.1;83.9) 
2 11 81.9%  

(17.0;98.1) 
HPV-59 73 68 -7.5%  

(<0.0;23.8) 
1 5 80.0%  

(<0.0;99.6) 
HPV-68 165 169 2.6%  

(<0.0;21.9) 
11 15 26.8%  

(<0.0;69.6) 
Other types 
HPV-51 349 416 16.6%  

(3.6;27.9) 
21 46 54.4%  

(22.0;74.2) 
HPV-56 226 215 -5.3%  

(<0.0;13.1) 
7 13 46.1%  

(<0.0;81.8) 
HPV-66 211 215 2.3%  

(<0.0;19.6) 
7 16 56.4%  

(<0.0;84.8) 
n= number of cases 
(1)  ATP: includes women who received 3 doses of vaccine, were DNA negative at month 0 and at month 6 to 

the relevant HPV type. 
The limits of the confidence interval around the vaccine efficacy were calculated. When the value zero is 
included, i.e. when the lower limit of the CI is <0, the efficacy is not considered statistically significant. 
 

The efficacy against CIN3 was only demonstrated for HPV-31 and there was no evidence of protection 
against AIS for any of the HPV types. 

 
Clinical efficacy in women aged 26 years and older 
 
The efficacy of Cervarix was assessed in a double-blind, randomised Phase III clinical trial (HPV-015) 
that included a total of 5,778 women aged 26-72 years (median: 37.0 years). The study was conducted 
in North America, Latin America, Asia Pacific and Europe. Final analysis was performed at study 
conclusion, 7 years after 1st vaccination.  
The primary endpoint was a combination of a virological and a histopathological endpoint: HPV-
16/18 related 6-month persistent infection and/or CIN1+. The primary analyses of efficacy were 
performed on the ATP cohort for efficacy and the TVC which included a subset of up to 15% of 
women with a history of HPV-associated infection or disease (defined as two or more abnormal 
smears in sequence, abnormal colposcopy, or biopsy or treatment of the cervix after abnormal smear 
or colposcopy findings). Inclusion of this subset allowed assessment of prophylactic efficacy in a 
population that is thought to reflect a real-world setting, as adult women are the age group generally 
targeted for cervical screening.  

 
Vaccine efficacy at study conclusion is summarised in the following table.  
 



13 

There is no evidence whether prevention of persistent infection that lasts for at least 6 months is a 
relevant surrogate marker for cervical cancer prevention in women aged 26 years and above. 
 
Table 7 - Vaccine efficacy at study conclusion in study HPV-015 

Endpoint ATP(1) TVC(2) 
Cervarix Control % Efficacy 

(96.2% CI) 
Cervarix Control % Efficacy 

(96.2% CI) n/N n/N n/N n/N 
HPV-16/18 

6M PI 
and/or 
CIN1+ 

7/1,852 71/1,818 90.5%  
(78.6; 96.5) 

93/2,768 209/2,778 56.8%  
(43.8; 67.0) 

6M PI 6/1,815 67/1,786 91.4%  
(79.4; 97.1) 

74/2,762 180/2,775 60%  
(46.4; 70.4) 

CIN2+ 1/1,852 6/1,818 83.7%  
(<0.0; 99.7) 

33/2,733 51/2,735 35.8%  
(<0.0; 61.0) 

ASC-US+ 3/1,852 47/1,818 93.8%  
(79.9; 98.9) 

38/2,727 114/2,732 67.3%  
(51.4; 78.5) 

6M PI in 
subjects 

seropositive 
at baseline 

only  

3/851 13/837 78%  
(15.0; 96.4) 

 42/1,211  65/1,192 38.7%  
(6.3; 60.4) 

Cross protective efficacy 

HPV-31 
6M PI 

10/2,073 29/2,090 65.8%  
(24.9; 85.8) 

51/2,762 71/2,775 29%  
(<0.0; 52.5) 

HPV-45 
6M PI  

9/2,106 30/2,088 70.7%  
(34.2; 88.4) 

22/2,762 60/2,775 63.9%  
(38.6; 79.6) 

HPV-31 
ASC-US+ 

5/2,117 23/2,127 78.4%  
(39.1; 94.1) 

34/2,727 55/2,732 38.7%  
(2.0; 62.3) 

HPV-45 
ASC-US+  

5/2,150 23/2,125 78.7%  
(40.1; 94.1) 

13/2,727 38/2,732 66.1%  
(32.7; 84.1) 

N = number of subjects in each group 
n = number of subjects reporting at least one event in each group 
6M PI = 6-month persistent infection 
CI = Confidence Interval 
ASC-US= Atypical Cells of Undetermined Significance (abnormal cytology) 
(1) 3 doses of vaccine, DNA negative and seronegative at month 0 (unless specified) and DNA negative at month 
6 for the relevant HPV type (HPV-16 and/or HPV-18) 
(2) at least one dose of vaccine, irrespective of HPV DNA and serostatus (unless specified) at month 0. Includes 
15% of subjects with previous history of HPV disease/infection 
 
Efficacy against ≥ASC-US (abnormal cytology) associated with oncogenic non-vaccine types was 
37.2% (96.2% CI [21.3; 50.1]) (ATP). 
 
Efficacy against CIN1+ irrespective of the HPV type detected in the lesion was 22.9% (96.2% CI [4.8; 
37.7]) (TVC).   
 
There was no evidence of protection from disease caused by HPV in subjects aged 25 years and above 
who were DNA positive and/ or with abnormal cytology at study entry. 
 
Immunogenicity 
 
Immune response to Cervarix after the primary vaccination course 
 
No minimal antibody level associated with protection against CIN of grade 2 or 3 or against persistent 
infection associated with vaccine HPV types has been identified for HPV vaccines. 
 



14 

The antibody response to HPV-16 and HPV-18 was measured using a type-specific direct ELISA 
(version 2, MedImmune methodology, modified by GSK) which was shown to correlate with the 
pseudovirion-based neutralisation assay (PBNA).  
 
The immunogenicity induced by three doses of Cervarix has been evaluated in 5,465 female subjects 
from 9 to 55 years of age and over 800 male subjects aged 10 to 18 years. 
 
In clinical trials, more than 99% of initially seronegative subjects had seroconverted to both HPV 
types 16 and 18 one month after the third dose. Vaccine-induced IgG Geometric Mean Titres (GMT) 
were well above titres observed in women previously infected but who cleared HPV infection (natural 
infection). Initially seropositive and seronegative subjects reached similar titres after vaccination. 
 
Persistence of Immune Response to Cervarix 
 
Study 001/007, which included women from 15 to 25 years of age at the time of vaccination, 
evaluated the immune response against HPV-16 and HPV-18 up to 76 months after administration of 
the first vaccine dose. In study 023 (a subset of study 001/007), the immune response continued to be 
evaluated up to 113 months. 92 subjects in the vaccine group had immunogenicity data at the [M107-
M113] interval after the first vaccine dose with a median follow-up of 8.9 years. Of these subjects, 
100% (95% CI: 96.1;100) remained seropositive for HPV-16 and HPV-18 in the ELISA assay. 
Vaccine-induced IgG GMTs for both HPV-16 and HPV-18 peaked at month 7 and then declined to 
reach a plateau from month 18 up to the [M107-M113] interval with ELISA GMTs for both HPV-16 
and HPV-18 at least still 10-fold higher than the ELISA GMTs observed in women who cleared a 
natural HPV infection. 
In study 008, immunogenicity up to month 48 was similar to the response observed in study 001. A 
similar kinetic profile was observed with the neutralising antibodies. 
 
In another clinical trial (study 014) performed in women aged 15 to 55 years, all subjects 
seroconverted to both HPV types 16 and 18 after the third dose (at month 7).  The GMTs were, 
however, lower in women above 25 years. 470 subjects (142 aged 15-25 years, 172 aged 26-45 years 
and 156 aged 46-55 years) who completed study HPV-014 and received the 3-dose schedule were 
followed-up for up to 10 years in the extension study HPV-060. Ten years after administration of the 
first dose, 100% of subjects in the 15-25 years group, 99.2% in the 26-45 years group and 96.3% in 
the 46-55 years group were still seropositive for HPV-16, and 99.2%, 93.7% and 83.8% for HPV-18, 
respectively. In all age groups, GMTs remained at least 5- to 32-fold for HPV-16 and 3- to 14-fold for 
HPV-18 above those elicited in women who cleared a natural infection for both antigens. 
 
Evidence of Anamnestic (Immune Memory) Response 
 
In study 024 (a subset of study 001/007), a challenge dose of Cervarix was administered to 65 subjects 
at a mean interval of 6.8 years after the administration of the first vaccine dose. An anamnestic 
immune response to HPV-16 and HPV-18 (by ELISA) was observed one week and one month after 
the challenge dose, GMTs one month after the challenge dose exceeded those observed one month 
after the primary 3-dose vaccination. 
 
Bridging the efficacy of Cervarix from young adult women to adolescents  
 
In a pooled analysis (HPV-029,-30 & -48), 99.7% and 100% of females aged 9 years seroconverted to 
HPV types 16 and 18, respectively after the third dose (at month 7) with GMTs at least 1.4-fold and 
2.4-fold higher as compared to females aged 10-14 years and 15 to 25 years, respectively. 
 
In two clinical trials (HPV-012 & -013) performed in girls aged 10 to 14 years, all subjects 
seroconverted to both HPV types 16 and 18 after the third dose (at month 7) with GMTs at least 2-fold 
higher as compared to women aged 15 to 25 years. 
 
In clinical trials (HPV-070 and HPV-048) performed in girls aged 9 to 14 years receiving a 2-dose 
schedule (0, 6 months or 0, 12 months) and young women aged 15-25 years receiving Cervarix 



15 

according to the standard 0, 1, 6 months schedule, all subjects seroconverted to both HPV types 16 and 
18 one month after the second dose. The immune response after 2 doses in females aged 9 to 14 years 
was non-inferior to the response after 3 doses in women aged 15 to 25 years. 
 
On the basis of these immunogenicity data, the efficacy of Cervarix is inferred from 9 to 14 years of 
age. 
 
Duration of the immune response in women aged 26 years and older  
 
In the Phase III study (HPV-015) in women 26 years and older all subjects seroconverted one month 
after the third dose. At the 84-month time point, i.e. 78 months after completion of the full vaccination 
course, 99.3% and 95.9% of initially seronegative women remained seropositive for anti-HPV-16 and 
anti-HPV-18 antibodies, respectively. All initially seropositive women remained seropositive for both 
anti-HPV-16 and anti-HPV-18 antibodies. Antibody titers peaked at month 7 then gradually declined 
up to month 18 and stabilized to reach a plateau up to month 84. 
 
Immunogenicity in males aged 10 to 18 years 
 
Immunogenicity in males was assessed in 2 clinical trials HPV-011 (N=173) and HPV-040 (N=556). 
The data showed comparable immunogenicity in males and females. In study HPV-011, all subjects 
seroconverted to both HPV-16 and 18 and GMT levels were non inferior to those observed in females 
aged 15 to 25 years in study HPV-012. 
 
Bridging of clinical efficacy against anal lesions and cancers  
 
No efficacy study against anal premalignant lesions has been conducted with Cervarix. However, 
studies conducted in girls aged 9 to 14 years (study HPV-071) and in women aged 18 to 45 years 
(study HPV-010) have consistently shown a higher immune response with Cervarix than with the 
comparator for which efficacy data against anal premalignant lesions are conclusive and have shown 
protection. 
 
Immunogenicity in HIV infected women 
 
Two clinical studies assessed safety and immunogenicity of Cervarix: 

1. In study HPV-020, conducted in South Africa, 22 HIV uninfected and 42 HIV infected 
subjects (WHO clinical stage 1; ATP cohort for immunogenicity) received Cervarix. 

2. Study HPV-019, a comparative study of Cervarix and quadrivalent HPV vaccine was 
conducted in 289 (ATP cohort = 157) HIV uninfected and 257 (ATP cohort = 166) HIV 
infected female subjects aged 15-25 years in Brazil, Estonia, India and Thailand.  

At study entry, HIV infected subjects in both studies had to: be asymptomatic regardless of their prior 
clinical stage; have undetectable viral load (i.e., viral load < 400 copies/ml) for at least six months if 
on antiretroviral therapy (ART) (HPV-020) or highly active antiretroviral therapy (HAART) for at 
least one year (HPV-019); not be diagnosed with active tuberculosis (TB) or on TB therapy;  in HPV-
019 only - have a CD4 cell count > 350 cells/mm3.  
In both studies, seroconversion at month 7 in HIV infected subjects receiving Cervarix was 100% for 
both antigens in the ATP cohort. In HPV-019, seropositivity at month 24 after Cervarix vaccination 
was 100% for HPV-16 antibodies and >96% for HPV-18 antibodies with a Geometric Mean 
Concentration (GMC) level more than 12 times higher than the response to natural HPV infection.  
In both studies, the antibody GMCs in HIV infected subjects appeared lower than in the HIV negative 
subjects (non-overlapping 95% confidence interval). In HPV-019, superiority of immune responses 
(neutralizing antibodies GMT ratios) to both HPV-16 and HPV-18 antigens was demonstrated with 
Cervarix compared to quadrivalent HPV vaccine, at month 7 in HIV infected subjects. The clinical 
relevance of these observations is unknown. No clinical efficacy data exist about protection against 
persistent infection or precancerous lesions among HIV infected women. 
 
The observed reactogenicity and safety profile of Cervarix in HIV infected women was in line with the 
known safety profile in healthy subjects (see section 4.8). 



16 

 
5.2 Pharmacokinetic properties 
 
Not applicable. 
 
5.3 Preclinical safety data 
 
Non-clinical data reveal no special hazard for humans based on conventional studies of safety 
pharmacology, acute and repeated dose toxicity, local tolerance, fertility, embryo-foetal and postnatal 
toxicity (up to the end of the lactation period).  
 
Serological data suggest a transfer of anti-HPV-16 and anti-HPV-18 antibodies via the milk during the 
lactation period in rats. However, it is unknown whether vaccine-induced antibodies are excreted in 
human breast milk. 
 
 
6.  PHARMACEUTICAL PARTICULARS 
 
6.1 List of excipients 
 
Sodium chloride (NaCl) 
Sodium dihydrogen phosphate dihydrate (NaH2PO4.2 H2O) 
Water for injections 
 
For adjuvants, see section 2. 
 
6.2 Incompatibilities 
 
In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal 
products. 
 
6.3 Shelf life 
 
5 years. 
 
Cervarix should be administered as soon as possible after being removed from the refrigerator.  
 
However, stability has been demonstrated when stored outside the refrigerator for up to 3 days at 
temperatures between 8°C and 25°C or for up to 1 day at temperatures between 25°C and 37°C. If not 
used at the end of this period the vaccine should be discarded. 
 
Multidose vial 
After first opening, immediate use is recommended. If not used immediately, the vaccine should be 
stored in a refrigerator (2°C – 8°C). If not used within 6 hours it should be discarded. 
 
6.4 Special precautions for storage 
 
Store in a refrigerator (2°C – 8°C). 
Do not freeze. 
Store in the original package in order to protect from light. 
 
Multidose vial 
For storage after first opening, see section 6.3. 
 
6.5 Nature and contents of container 
 
Pre-filled syringe 



17 

0.5 ml of suspension in a pre-filled syringe (type I glass) with a plunger stopper (rubber butyl) with or 
without needles.  
 
Pack sizes of 1 and 10 pre-filled syringes with or without needles. 
 
Vial 
0.5 ml of suspension in a vial (type I glass) for 1 dose with a stopper (rubber butyl).  
 
Pack sizes of 1, 10 and 100 vials. 
 
Multidose vial 
1 ml of suspension in a vial (type I glass) for 2 doses with a stopper (rubber butyl). 
 
Pack sizes of 1, 10 and 100 vials. 
 
Not all pack sizes may be marketed. 
 
6.6 Special precautions for disposal and other handling 
 
Pre-filled syringe 
A fine white deposit with a clear colourless supernatant may be observed upon storage of the syringe. 
This does not constitute a sign of deterioration. 
 
The content of the syringe should be inspected visually both before and after shaking for any foreign 
particulate matter and/or abnormal physical appearance prior to administration.  
In the event of either being observed, discard the vaccine. 
 
The vaccine should be well shaken before use. 
 
Instructions for administration of the vaccine in pre-filled syringe 
 
 
1. Holding the syringe barrel in one hand  
(avoid holding the syringe plunger),  
unscrew the syringe cap by twisting it anticlockwise. 
 
 
 
 
 
2. To attach the needle to the syringe,  
twist the needle clockwise into the syringe  
until you feel it lock.  
 
 
3. Remove the needle protector, which on 
 occasion can be a little stiff. 
 
 
4. Administer the vaccine. 
 
 
 
 
 
Vial 

Syringe plunger 

Syringe barrel Syringe cap 

Needle protector 



18 

A fine white deposit with a clear colourless supernatant may be observed upon storage of the vial. This 
does not constitute a sign of deterioration. 
 
The content of the vial should be inspected visually both before and after shaking for any foreign 
particulate matter and/or abnormal physical appearance prior to administration.  
In the event of either being observed, discard the vaccine. 
 
The vaccine should be well shaken before use. 
 
Multidose vial 
A fine white deposit with a clear colourless supernatant may be observed upon storage of the vial. This 
does not constitute a sign of deterioration. 
 
The content of the vial should be inspected visually both before and after shaking for any foreign 
particulate matter and/or abnormal physical appearance prior to administration.  
In the event of either being observed, discard the vaccine. 
 
The vaccine should be well shaken before use. 
 
When using a multidose vial, each 0.5 ml dose should be withdrawn using a sterile needle and syringe; 
precautions should be taken to avoid contamination of the contents. 
 
Any unused medicinal product or waste material should be disposed of in accordance with local 
requirements. 
 
 
7. MARKETING AUTHORISATION HOLDER 
 
GlaxoSmithKline Biologicals s.a. 
Rue de l'Institut 89 
B-1330 Rixensart, Belgium 
 
8. MARKETING AUTHORISATION NUMBER(S)  
 
Pre-filled syringe 
EU/1/07/419/004 
EU/1/07/419/005 
EU/1/07/419/006 
EU/1/07/419/007 
EU/1/07/419/008 
EU/1/07/419/009 
 
Vial 
EU/1/07/419/001 
EU/1/07/419/002 
EU/1/07/419/003 
 
Multidose vial 
EU/1/07/419/010 
EU/1/07/419/011 
EU/1/07/419/012 
 
 
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION 
 
Date of first authorisation: 20 September 2007. 
Date of latest renewal: 17 September 2012. 



19 

 
 
10. DATE OF REVISION OF THE TEXT 
 
Detailed information on this medicinal product is available on the website of the European Medicines 
Agency http://www.ema.europa.eu. 
 

http://www.ema.europa.eu/
http://www.ema.europa.eu/


20 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

ANNEX II 
 
A. MANUFACTURER OF THE BIOLOGICAL ACTIVE 

SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR 
BATCH RELEASE 

 
B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY 

AND USE 
 
C. OTHER CONDITIONS AND REQUIREMENTS OF THE 

MARKETING AUTHORISATION 
 
D. CONDITIONS OR RESTRICTIONS WITH REGARD TO 

THE SAFE AND EFFECTIVE USE OF THE MEDICINAL 
PRODUCT 

 
 

 



21 

 
A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND 

MANUFACTURER RESPONSIBLE FOR BATCH RELEASE 
 
Name and address of the manufacturers of the biological active substance 
 
GlaxoSmithKline Biologicals SA 
Parc de la Noire Epine 
rue Flemming  
20-1300 Wavre 
Belgium 
 
Name and address of the manufacturer responsible for batch release 
 
GlaxoSmithKline Biologicals S.A. 
89, rue de l'Institut 
BE-1330 Rixensart 
Belgium 
 
 
B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE 
 
Medicinal product subject to medical prescription. 
 
• Official batch release 
 
In accordance with Article 114 of Directive 2001/83/EC, the official batch release will be undertaken 
by a state laboratory or a laboratory designated for that purpose. 
 
 
C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING 

AUTHORISATION 
 
• Periodic safety update reports (PSURs) 
 
The requirements for submission of PSURs for this medicinal product are set out in the list of Union 
reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any 
subsequent updates published on the European medicines web-portal. 
 
 
D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND 

EFFECTIVE USE OF THE MEDICINAL PRODUCT 
 
• Risk management plan (RMP) 
 
The marketing authorisation holder (MAH) shall perform the required pharmacovigilance activities 
and interventions detailed in the agreed RMP presented in Module 1.8.2 of the marketing authorisation 
and any agreed subsequent updates of the RMP.  
 
An updated RMP should be submitted: 

• At the request of the European Medicines Agency; 
• Whenever the risk management system is modified, especially as the result of new information 

being received that may lead to a significant change to the benefit/risk profile or as the result 
of an important (pharmacovigilance or risk minimisation) milestone being reached. 

 



22 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

ANNEX III 
 

LABELLING AND PACKAGE LEAFLET 
 



23 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

A. LABELLING 



24 

 
PARTICULARS TO APPEAR ON THE OUTER PACKAGING 
MONODOSE VIAL, PACK OF 1, 10, 100 
 
 
1. NAME OF THE MEDICINAL PRODUCT 
 
Cervarix suspension for injection in a vial 
Human Papillomavirus vaccine [Types 16, 18] (Recombinant, adjuvanted, adsorbed) 
 
 
2. STATEMENT OF ACTIVE SUBSTANCE(S) 
 
1 dose (0.5 ml) contains: 
 
HPV type 16 L1 protein1,2 20 micrograms 
HPV type 18 L1 protein1,2 20 micrograms 
 
1 adjuvanted by AS04 containing: 
3-O-desacyl-4’- monophosphoryl lipid A (MPL)2 50 micrograms 
 
2adsorbed on aluminium hydroxide, hydrated (Al(OH)3)  0.5 milligrams Al3+ in total  
 
 
3. LIST OF EXCIPIENTS 
 
Sodium chloride 
Sodium dihydrogen phosphate dihydrate 
Water for injections 
 
 
4. PHARMACEUTICAL FORM AND CONTENTS 
 
Suspension for injection 
1 vial 
1 dose (0.5 ml) 
 
10 vials 
10 x 1 dose (0.5 ml) 
 
100 vials 
100 x 1 dose (0.5 ml) 
 
 
5. METHOD AND ROUTE(S) OF ADMINISTRATION 
 
Read the package leaflet before use 
Intramuscular use 
Shake before use 
 
 
6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT 

OF THE SIGHT AND REACH OF CHILDREN 
 
Keep out of the sight and reach of children 



25 

 
 
7. OTHER SPECIAL WARNING(S), IF NECESSARY 
 
 
8. EXPIRY DATE 
 
EXP 
 
 
9. SPECIAL STORAGE CONDITIONS 
 
Store in a refrigerator 
Do not freeze 
Store in the original package in order to protect from light 
 
 
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS 

OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF 
APPROPRIATE 

 
 
11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER 
 
GlaxoSmithKline Biologicals s.a. 
Rue de l’Institut 89 
B-1330 Rixensart, Belgium 
 
 
12. MARKETING AUTHORISATION NUMBER(S)  
 
EU/1/07/419/001 – pack of 1 
EU/1/07/419/002 – pack of 10 
EU/1/07/419/003 – pack of 100 
 
 
13. BATCH NUMBER 
 
LOT: 
 
 
14. GENERAL CLASSIFICATION FOR SUPPLY 
 
 
15. INSTRUCTIONS ON USE 
 
 
16. INFORMATION IN BRAILLE 
 
Justification for not including Braille accepted 
 
 
17. UNIQUE IDENTIFIER – 2D BARCODE 
 



26 

2D barcode carrying the unique identifier included. 
 
 
18. UNIQUE IDENTIFIER - HUMAN READABLE DATA 
 
PC 
SN 
NN 



27 

 
PARTICULARS TO APPEAR ON THE OUTER PACKAGING 
MULTIDOSE VIAL, PACK OF 1, 10, 100 
 
 
1. NAME OF THE MEDICINAL PRODUCT 
 
Cervarix suspension for injection, multidose container 
Human Papillomavirus vaccine [Types 16, 18] (Recombinant, adjuvanted, adsorbed) 
 
 
2. STATEMENT OF ACTIVE SUBSTANCE(S) 
 
1 dose (0.5 ml) contains: 
 
HPV type 16 L1 protein1,2 20 micrograms 
HPV type 18 L1 protein1,2 20 micrograms 
 
1 adjuvanted by AS04 containing: 
3-O-desacyl-4’- monophosphoryl lipid A (MPL)2 50 micrograms 
 
2adsorbed on aluminium hydroxide, hydrated (Al(OH)3)  0.5 milligrams Al3+ in total  
 
 
3. LIST OF EXCIPIENTS 
 
Sodium chloride 
Sodium dihydrogen phosphate dihydrate 
Water for injections 
 
 
4. PHARMACEUTICAL FORM AND CONTENTS 
 
Suspension for injection 
1 multidose vial 
2 doses (1 ml) 
 
10 multidose vials 
10 x 2 doses (1 ml) 
 
100 multidose vials 
100 x 2 doses (1 ml) 
 
 
5. METHOD AND ROUTE(S) OF ADMINISTRATION 
 
Read the package leaflet before use 
Intramuscular use 
Shake before use 
 
 
6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT 

OF THE SIGHT AND REACH OF CHILDREN 
 
Keep out of the sight and reach of children 



28 

 
 
7. OTHER SPECIAL WARNING(S), IF NECESSARY 
 
 
8. EXPIRY DATE 
 
EXP 
 
After first opening, use immediately or within 6 hours if stored in a refrigerator  
 
 
9. SPECIAL STORAGE CONDITIONS 
 
Store in a refrigerator 
Do not freeze 
Store in the original package in order to protect from light 
 
 
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS 

OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF 
APPROPRIATE 

 
 
11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER 
 
GlaxoSmithKline Biologicals s.a. 
Rue de l’Institut 89 
B-1330 Rixensart, Belgium 
 
 
12. MARKETING AUTHORISATION NUMBER(S)  
 
EU/1/07/419/010 – pack of 1 
EU/1/07/419/011 – pack of 10 
EU/1/07/419/012 – pack of 100 
 
 
13. BATCH NUMBER 
 
LOT: 
 
 
14. GENERAL CLASSIFICATION FOR SUPPLY 
 
 
15. INSTRUCTIONS ON USE 
 
 
16. INFORMATION IN BRAILLE 
 
Justification for not including Braille accepted 
 
 



29 

17. UNIQUE IDENTIFIER – 2D BARCODE 
 
2D barcode carrying the unique identifier included. 
 
 
18. UNIQUE IDENTIFIER - HUMAN READABLE DATA 
 
PC 
SN 
NN 



30 

 
PARTICULARS TO APPEAR ON THE OUTER PACKAGING 
PRE-FILLED SYRINGE WITH OR WITHOUT NEEDLE, PACK OF 1, 10 
 
 
1. NAME OF THE MEDICINAL PRODUCT 
 
Cervarix suspension for injection in pre-filled syringe 
Human Papillomavirus vaccine [Types 16, 18] (Recombinant, adjuvanted, adsorbed) 
 
 
2. STATEMENT OF ACTIVE SUBSTANCE(S) 
 
1 dose (0.5 ml) contains: 
 
HPV type 16 L1 protein1,2 20 micrograms 
HPV type 18 L1 protein1,2 20 micrograms 
 
1 adjuvanted by AS04 containing: 
3-O-desacyl-4’- monophosphoryl lipid A (MPL)2 50 micrograms 
 
2adsorbed on aluminium hydroxide, hydrated (Al(OH)3)  0.5 milligrams Al3+ in total  
 
 
3. LIST OF EXCIPIENTS 
 
Sodium chloride 
Sodium dihydrogen phosphate dihydrate 
Water for injections 
 
 
4. PHARMACEUTICAL FORM AND CONTENTS 
 
Suspension for injection in pre-filled syringe 
1 pre-filled syringe 
1 dose (0.5 ml) 
 
10 pre-filled syringes 
10 x 1 dose (0.5 ml) 
 
1 pre-filled syringe + 1 needle 
1 dose (0.5 ml) 
 
10 pre-filled syringes + 10 needles 
10 x 1 dose (0.5 ml) 
 
1 pre-filled syringe + 2 needles 
1 dose (0.5 ml) 
 
10 pre-filled syringes + 20 needles 
10 x 1 dose (0.5 ml) 
 
 
5. METHOD AND ROUTE(S) OF ADMINISTRATION 
 
Read the package leaflet before use 



31 

Intramuscular use 
Shake before use 
 
 
6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT 

OF THE SIGHT AND REACH OF CHILDREN 
 
Keep out of the sight and reach of children 
 
 
7. OTHER SPECIAL WARNING(S), IF NECESSARY 
 
 
8. EXPIRY DATE 
 
EXP 
 
 
9. SPECIAL STORAGE CONDITIONS 
 
Store in a refrigerator 
Do not freeze 
Store in the original package in order to protect from light 
 
 
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS 

OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF 
APPROPRIATE 

 
 
11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER 
 
GlaxoSmithKline Biologicals s.a. 
Rue de l’Institut 89 
B-1330 Rixensart, Belgium 
 
 
12. MARKETING AUTHORISATION NUMBER(S)  
 
EU/1/07/419/008 – pack of 1 without needle 
EU/1/07/419/009 – pack of 10 without needle 
EU/1/07/419/004 – pack of 1 with 1 needle 
EU/1/07/419/006 – pack of 10 with 10 needles 
EU/1/07/419/005 – pack of 1 with 2 needles 
EU/1/07/419/007 – pack of 10 with 20 needles 
 
 
13. BATCH NUMBER 
 
LOT: 
 
 
14. GENERAL CLASSIFICATION FOR SUPPLY 
 
 



32 

 
15. INSTRUCTIONS ON USE 
 
 
16. INFORMATION IN BRAILLE 
 
Justification for not including Braille accepted 
 
 
17. UNIQUE IDENTIFIER – 2D BARCODE 
 
2D barcode carrying the unique identifier included. 
 
 
18. UNIQUE IDENTIFIER - HUMAN READABLE DATA 
 
PC 
SN 
NN 
 



33 

 
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS 
MONODOSE VIAL LABEL 
 
 
1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION 
 
Cervarix 
Suspension for injection 
 
I.M. 
 
 
2. METHOD OF ADMINISTRATION 
 
 
3. EXPIRY DATE 
 
EXP 
 
 
4. BATCH NUMBER 
 
Lot 
 
 
5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 
 
1 dose (0.5 ml) 
 
 
6. OTHER 
 
 



34 

 
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS 
MULTIDOSE VIAL LABEL 
 
 
1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION 
 
Cervarix 
Suspension for injection 
 
I.M. 
 
 
2. METHOD OF ADMINISTRATION 
 
 
3. EXPIRY DATE 
 
EXP 
 
 
4. BATCH NUMBER 
 
Lot 
 
 
5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 
 
2 doses (1 ml) 
 
 
6. OTHER 
 
 



35 

 
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS 
PRE-FILLED SYRINGE LABEL 
 
 
1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION 
 
Cervarix 
Suspension for injection in pre-filled syringe 
 
I.M. 
 
 
2. METHOD OF ADMINISTRATION 
 
 
3. EXPIRY DATE 
 
EXP 
 
 
4. BATCH NUMBER 
 
Lot 
 
 
5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 
 
1 dose (0.5 ml) 
 
 
6. OTHER 
 
 



36 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

B. PACKAGE LEAFLET 
 



37 

 
 

Package leaflet: Information for the user 
 

Cervarix suspension for injection in a vial 
Human Papillomavirus vaccine [Types 16, 18] (Recombinant, adjuvanted, adsorbed) 

 
Read all of this leaflet carefully before you start receiving this vaccine because it contains 
important information for you. 
- Keep this leaflet. You may need to read it again. 
- If you have any further questions, ask your doctor or pharmacist. 
- This medicine has been prescribed for you only. Do not pass it on to others.  
- If you get any side effects, talk to your doctor or pharmacist. This includes any possible side 

effects not listed in this leaflet. See section 4. 
 
What is in this leaflet:  
1. What Cervarix is and what it is used for 
2. What you need to know before you receive Cervarix 
3. How Cervarix is given 
4. Possible side effects 
5. How to store Cervarix 
6. Contents of the pack and other information 
 
 
1. What Cervarix is and what it is used for 
 
Cervarix is a vaccine intended to protect from the age of 9 years against the diseases caused by 
infection with Human Papillomaviruses (HPV). 
 
These diseases include: 
- cervical cancer (cancer of the cervix i.e. lower part of the uterus or womb) and anal cancer,  
- precancerous cervical, vulvar, vaginal and anal lesions (changes in genital or anal cells that have a 

risk of turning into cancer). 
 
The Human Papillomavirus (HPV) types contained in the vaccine (HPV types 16 and 18) are 
responsible for approximately 70% of cervical cancers, 90% of anal cancers, 70% of HPV-related pre-
cancerous lesions of the vulva and vagina and 78% of HPV-related pre-cancerous lesions of the anus. 
Other HPV types can also cause ano-genital cancers. Cervarix does not protect against all HPV types. 
 
When a female or a male individual is vaccinated with Cervarix, the immune system (the body’s 
natural defence system) will make antibodies against HPV types 16 and 18. 
 
Cervarix is not infectious and so, it cannot cause HPV related diseases. 
 
Cervarix is not used to treat HPV related diseases already present at the time of vaccination. 
 
Cervarix should be used in accordance with official guidelines. 
 
 
2. What you need to know before you receive Cervarix 
 
Cervarix should not be given:  
 
• if you are allergic to any of the active substances or any of the other ingredients of this vaccine 

(listed in section 6). Signs of an allergic reaction may include itchy skin rash, shortness of 
breath and swelling of the face or tongue. 
 



38 

 
Warnings and precautions 
Talk to your doctor or pharmacist before you are given Cervarix 
• if you have a bleeding problem or bruise easily. 
• if you have any disease which reduces your resistance to infection such as HIV infection. 
• if you have a severe infection with a high temperature. It might be necessary to postpone the 

vaccination until recovery. A minor infection such as a cold should not be a problem, but talk to 
the doctor first. 

 
Fainting can occur (mostly in adolescents) following, or even before, any needle injection. Therefore 
tell the doctor or nurse if you or your child fainted with a previous injection. 
 
As with all vaccines, Cervarix may not fully protect all people who are vaccinated. 
 
Cervarix does not protect people from diseases caused by infection with HPV types 16 or 18 if they 
are already infected with Human Papillomavirus type 16 or 18 at the time of vaccination. 
 
Although vaccination may protect you against cervical cancer, it is not a substitute for regular cervical 
screening. You should continue to follow your doctor’s advice on cervical smear/Pap test (test to 
screen for changes in cells of the cervix caused by an HPV infection) and preventative and protective 
measures. 
 
As Cervarix will not protect against all types of Human Papillomavirus, appropriate precautions 
against exposure to HPV and sexually transmitted diseases should continue to be used. 
 
Cervarix will not protect against other diseases that are not caused by Human Papillomavirus. 
 
Other medicines and Cervarix 
Cervarix can be given with a combined booster vaccine containing diphtheria (d), tetanus (T) and 
pertussis [acellular] (pa) with or without inactivated poliomyelitis (IPV), (dTpa, dTpa -IPV vaccines), 
with a combined hepatitis A and hepatitis B vaccine (Twinrix) or a hepatitis B vaccine (Engerix B), or 
with a meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate vaccine (MenACWY-TT), 
at a separate injection site (another part of your body, e.g. the other arm) during the same visit. 
 
Cervarix may not have an optimal effect if used with medicines that suppress the immune system. 
 
In clinical trials, oral contraceptives (e.g. the pill) did not reduce the protection obtained by Cervarix. 
 
Tell your doctor if you are taking, have recently taken, might take any other medicines, or have 
recently received any other vaccine. 
 
Pregnancy, breast-feeding and fertility 
If you are pregnant, if pregnancy occurs during the course of vaccination or if you are trying to 
become pregnant it is recommended to postpone or interrupt vaccination until after completion of the 
pregnancy. 
 
If you are pregnant or breast-feeding, think that you may be pregnant or are planning to have a baby, 
ask your doctor for advice before you are given this vaccine. 
 
Driving and using machines 
Cervarix is not likely to affect your ability to drive or use machines. However, do not drive or use any 
machines if you are feeling unwell. 
 
Cervarix contains sodium chloride. 
 
This medicinal product contains less than 1 mmol sodium (23 mg) per dose, i.e. essentially “sodium-
free”. 



39 

 
 
3. How Cervarix is given  
 
How the vaccine is given 
The doctor or nurse will give Cervarix as an injection into the muscle of the upper arm.  
 
How much is given 
Cervarix is intended for use from 9 years of age onwards.  
 
The total number of injections you will receive depends on your age at the time of the first injection. 
 
If you are between 9 and 14 years old 
 
You will receive 2 injections: 
 
First injection: at chosen date 
Second injection: given between 5 and 13 months after first injection 
 
If you are 15 years old or above 
 
You will receive 3 injections: 
 
First injection: at chosen date 
Second injection: 1 month after first injection 
Third injection: 6 months after first injection 
 
If necessary, the vaccination schedule can be more flexible. Please speak to your doctor for more 
information. 
 
When Cervarix is given for the first dose, it is recommended that Cervarix (and not another vaccine 
against HPV) be given for the complete vaccination course. 
 
Cervarix is not recommended for use below 9 years of age. 
 
The vaccine should never be given into a vein. 
 
If you miss a dose 
It is important that you follow the instructions of your doctor or nurse regarding return visits. If you 
forget to go back to your doctor at the scheduled time, ask your doctor for advice. 
 
If you do not finish the complete vaccination course (two or three injections depending on your age at 
vaccination), you may not get the best response and protection from the vaccination. 
 
 
4. Possible side effects 
 
Like all medicines, this vaccine can cause side effects, although not everybody gets them. 
 
Side effects that occurred during clinical trials with Cervarix were as follows: 
 
♦ Very common (side effects which may occur in more than 1 per 10 doses of vaccine): 

• pain or discomfort at the injection site 
• redness or swelling at the injection site 
• headache 
• aching muscles, muscle tenderness or weakness (not caused by exercise) 
• tiredness 



40 

 
♦ Common (side effects which may occur in less than 1 per 10 but more than 1 per 100 doses of 

vaccine):  
• gastrointestinal symptoms including nausea, vomiting, diarrhoea and abdominal pain 
• itching, red skin rash, hives (urticaria) 
• joint pain 
• fever (≥38°C) 

 
♦ Uncommon (side effects which may occur in less than 1 per 100 but more than 1 per 1,000 

doses of vaccine): 
• upper respiratory tract infection (infection of the nose, throat or trachea) 
• dizziness 
• other injection site reactions such as hard lump, tingling or numbness. 

 
Side effects that have been reported during marketed use of Cervarix include: 
 
• allergic reactions. These can be recognised by: 

itchy rash of the hands and feet, 
swelling of the eyes and face, 
difficulty in breathing or swallowing, 
sudden drop in blood pressure and loss of consciousness. 

These reactions will usually occur before leaving the doctor’s surgery.  However, if your child gets 
any of these symptoms you should contact a doctor urgently. 

• swollen glands in the neck, armpit or groin 
• fainting sometimes accompanied by shaking or stiffness. 
 
Reporting of side effects 
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system 
listed in Appendix V. By reporting side effects you can help provide more information on the safety of 
this medicine. 
 
 
5. How to store Cervarix 
 
Keep this vaccine out of the sight and reach of children. 
 
Do not use this vaccine after the expiry date which is stated on the carton. The expiry date refers to the 
last day of that month. 
 
Store in a refrigerator (2°C – 8°C). 
Do not freeze.  
Store in the original package in order to protect from light. 
 
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help to protect the environment. 
 
 
6. Contents of the pack and other information 
 
What Cervarix contains 
 
- The active substances are: 
 

Human Papillomavirus1 type 16 L1 protein2,3,4 20 micrograms 
Human Papillomavirus1 type 18 L1 protein2,3,4 20 micrograms 



41 

 
1Human Papillomavirus = HPV 
 
2adjuvanted by AS04 containing: 
3-O-desacyl-4’- monophosphoryl lipid A (MPL)3 50 micrograms 
 
3adsorbed on aluminium hydroxide, hydrated (Al(OH)3)  0.5 milligrams Al3+ in total 
 
4L1 protein in the form of non-infectious virus-like particles (VLPs) produced by recombinant 
DNA technology using a Baculovirus expression system which uses Hi-5 Rix4446 cells derived 
from the insect Trichoplusia ni. 
 

- The other ingredients are sodium chloride (NaCl), sodium dihydrogen phosphate dihydrate 
(NaH2PO4.2 H2O) and water for injections. 

 
What Cervarix looks like and contents of the pack 
 
Suspension for injection. 
 
Cervarix is a turbid white suspension. 
 
Cervarix is available in 1 dose vials (0.5 ml) in packs of 1, 10 and 100. 
 
Not all pack sizes may be marketed. 
 
Marketing Authorisation Holder and Manufacturer 
 
GlaxoSmithKline Biologicals s.a. 
Rue de l'Institut 89 
B-1330 Rixensart, Belgium 
 
For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder: 
 
Belgique/België/Belgien 
GlaxoSmithKline Pharmaceuticals s.a./n.v. 
Tél/Tel: + 32 10 85 52 00 
 

Lietuva 
GlaxoSmithKline Lietuva UAB 
Tel: +370 5 264 90 00 
info.lt@gsk.com 

 
България 
ГлаксоСмитКлайн ЕООД 
Тел. + 359 2 953 10 34 
 

 
Luxembourg/Luxemburg 
GlaxoSmithKline Pharmaceuticals s.a./n.v. 
Tél/Tel: + 32 10 85 52 00 

Česká republika 
GlaxoSmithKline s.r.o. 
Tel: + 420 2 22 00 11 11 
cz.info@gsk.com 
 

Magyarország 
GlaxoSmithKline Kft. 
Tel.: + 36-1-2255300 
 

Danmark 
GlaxoSmithKline Pharma A/S 
Tlf: + 45 36 35 91 00 
dk-info@gsk.com 
 

Malta 
GlaxoSmithKline (Malta) Ltd 
Tel: + 356 21 238131 
 

Deutschland 
GlaxoSmithKline GmbH & Co. KG 
Tel: + 49 (0)89 360448701 
produkt.info@gsk.com 

Nederland 
GlaxoSmithKline BV 
Tel: + 31 (0)30 69 38 100 
nlinfo@gsk.com 



42 

 
Eesti 
GlaxoSmithKline Eesti OÜ  
Tel: +372 667 6900 
estonia@gsk.com 
 

Norge 
GlaxoSmithKline AS 
Tlf: + 47 22 70 20 00 
 

Ελλάδα 
GlaxoSmithKline A.E.B.E 
Tηλ: + 30 210 68 82 100 
 

Österreich 
GlaxoSmithKline Pharma GmbH 
Tel: + 43 (0)1 97075 0 
at.info@gsk.com 

 
España 
GlaxoSmithKline, S.A. 
Tel: + 34 902 202 700 
es-ci@gsk.com  
 

 
Polska 
GSK Services Sp. z o.o. 
Tel.: + 48 (22) 576 9000 
 

France 
Laboratoire GlaxoSmithKline 
Tél: + 33 (0) 1 39 17 84 44 
diam@gsk.com 
 
Hrvatska 
GlaxoSmithKline d.o.o. 
Tel.: + 385 (0)1 6051999 
 

Portugal 
GlaxoSmithKline - Produtos Farmacêuticos, 
Lda. 
Tel: + 351 21 412 95 00 
FI.PT@gsk.com 
 
România 
GlaxoSmithKline (GSK) SRL 
Tel: +40 (0)21 3028 208 
 

Ireland 
GlaxoSmithKline (Ireland) Ltd 
Tel: + 353 (0)1 495 5000 
 

Slovenija 
GlaxoSmithKline d.o.o. 
Tel: + 386 (0) 1 280 25 00 
medical.x.si@gsk.com 
 

Ísland 
Vistor hf.  
Sími: +354 535 7000  

Slovenská republika 
GlaxoSmithKline Slovakia s.r.o. 
Tel.: + 421 (0)2 48 26 11 11 
recepcia.sk@gsk.com  
 

Italia 
GlaxoSmithKline S.p.A. 
Tel:+ 39 (0)45 9218 111 
 
 

Suomi/Finland 
GlaxoSmithKline Oy 
Puh/Tel: + 358 10 30 30 30 
Finland.tuoteinfo@gsk.com 
 

Κύπρος 
GlaxoSmithKline (Cyprus) Ltd 
Τηλ: + 357 22 39 70 00 
gskcyprus@gsk.com 
 

Sverige 
GlaxoSmithKline AB 
Tel: + 46 (0)8 638 93 00 
info.produkt@gsk.com  

Latvija 
GlaxoSmithKline Latvia SIA 
Tel: + 371 67312687 
lv-epasts@gsk.com 

United Kingdom 
GlaxoSmithKline UK 
Tel: +44 (0)800 221 441 
customercontactuk@gsk.com 
 

  
This leaflet was last revised in (MM/YYYY) 
 
Other sources of information 
 

mailto:gskcyprus@gsk.com
mailto:gskcyprus@gsk.com


43 

Detailed information on this medicine is available on the European Medicines Agency web site: 
http://www.ema.europa.eu. 
 
------------------------------------------------------------------------------------------------------------------------- 
 
The following information is intended for healthcare professionals only: 
 
Cervarix should be administered as soon as possible after being removed from the 
refrigerator. However, stability has been demonstrated when stored outside the 
refrigerator for up to 3 days at temperatures between 8°C and 25°C or for up to 1 day 
at temperatures between 25°C and 37°C. If not used at the end of this period the 
vaccine should be discarded. 
  
A fine white deposit with a clear colourless supernatant may be observed upon storage of the vial. This 
does not constitute a sign of deterioration. 
 
The content of the vial should be inspected visually both before and after shaking for any foreign 
particulate matter and/or abnormal physical appearance prior to administration.  
In the event of either being observed, discard the vaccine. 
 
The vaccine should be well shaken before use. 
 
Any unused medicinal product or waste material should be disposed of in accordance with local 
requirements. 



44 

 
Package leaflet: Information for the user 

 
Cervarix suspension for injection, multidose container 

Human Papillomavirus vaccine [Types 16, 18] (Recombinant, adjuvanted, adsorbed) 
 

Read all of this leaflet carefully before you start receiving this vaccine because it contains 
important information for you. 
- Keep this leaflet. You may need to read it again. 
- If you have any further questions, ask your doctor or pharmacist. 
- This medicine has been prescribed for you only. Do not pass it on to others.  
- If you get any side effects, talk to your doctor or pharmacist. This includes any possible side 

effects not listed in this leaflet. See section 4. 
 
What is in this leaflet:  
1. What Cervarix is and what it is used for 
2. What you need to know before you receive Cervarix 
3. How Cervarix is given 
4. Possible side effects 
5. How to store Cervarix 
6. Contents of the pack and other information 
 
 
1. What Cervarix is and what it is used for 
 
Cervarix is a vaccine intended to protect from the age of 9 years against the diseases caused by 
infection with Human Papillomaviruses (HPV). 
 
These diseases include: 
- cervical cancer (cancer of the cervix i.e. lower part of the uterus or womb) and anal cancer,  
- precancerous cervical, vulvar, vaginal and anal lesions (changes in genital or anal cells that have a 

risk of turning into cancer). 
 
The Human Papillomavirus (HPV) types contained in the vaccine (HPV types 16 and 18) are 
responsible for approximately 70% of cervical cancers, 90% of anal cancers, 70% of HPV-related pre-
cancerous lesions of the vulva and vagina and 78% of HPV-related pre-cancerous lesions of the anus. 
Other HPV types can also cause ano-genital cancers. Cervarix does not protect against all HPV types. 
 
When a female or a male individual is vaccinated with Cervarix, the immune system (the body’s 
natural defence system) will make antibodies against HPV types 16 and 18.  
Cervarix is not infectious and so, it cannot cause HPV related diseases. 
 
Cervarix is not used to treat HPV related diseases already present at the time of vaccination. 
 
Cervarix should be used in accordance with official guidelines. 
 
 
2. What you need to know before you receive Cervarix 
 
Cervarix should not be given:  
 
• if you are allergic to any of the active substances or any of the other ingredients of this vaccine 

(listed in section 6). Signs of an allergic reaction may include itchy skin rash, shortness of 
breath and swelling of the face or tongue. 

 
Warnings and precautions 
Talk to your doctor or pharmacist before you are given Cervarix 



45 

• if you have a bleeding problem or bruise easily. 
• if you have any disease which reduces your resistance to infection such as HIV infection. 
• if you have a severe infection with a high temperature. It might be necessary to postpone the 

vaccination until recovery. A minor infection such as a cold should not be a problem, but talk to 
the doctor first. 

 
Fainting can occur (mostly in adolescents) following, or even before, any needle injection. Therefore 
tell the doctor or nurse if you or your child fainted with a previous injection. 
 
As with all vaccines, Cervarix may not fully protect all people who are vaccinated. 
 
Cervarix does not protect people from diseases caused by infection with HPV types 16 or 18 if they 
are already infected with Human Papillomavirus type 16 or 18 at the time of vaccination. 
 
Although vaccination may protect you against cervical cancer, it is not a substitute for regular cervical 
screening. You should continue to follow your doctor’s advice on cervical smear/Pap test (test to 
screen for changes in cells of the cervix caused by an HPV infection) and preventative and protective 
measures. 
 
As Cervarix will not protect against all types of Human Papillomavirus, appropriate precautions 
against exposure to HPV and sexually transmitted diseases should continue to be used. 
 
Cervarix will not protect against other diseases that are not caused by Human Papillomavirus. 
 
Other medicines and Cervarix 
Cervarix can be given with a combined booster vaccine containing diphtheria (d), tetanus (T) and 
pertussis [acellular] (pa) with or without inactivated poliomyelitis (IPV), (dTpa, dTpa -IPV vaccines), 
with a combined hepatitis A and hepatitis B vaccine (Twinrix) or a hepatitis B vaccine (Engerix B), or 
with a meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate vaccine (MenACWY-TT), 
at a separate injection site (another part of your body, e.g. the other arm) during the same visit. 
 
Cervarix may not have an optimal effect if used with medicines that suppress the immune system. 
 
In clinical trials, oral contraceptives (e.g. the pill) did not reduce the protection obtained by Cervarix. 
 
Tell your doctor if you are taking, have recently taken, might take any other medicines, or have 
recently received any other vaccine. 
 
Pregnancy, breast-feeding and fertility 
If you are pregnant, if pregnancy occurs during the course of vaccination or if you are trying to 
become pregnant it is recommended to postpone or interrupt vaccination until after completion of the 
pregnancy. 
 
If you are pregnant or breast-feeding, think that you may be pregnant or are planning to have a baby, 
ask your doctor for advice before you are given this vaccine. 
 
Driving and using machines 
Cervarix is not likely to affect your ability to drive or use machines. However, do not drive or use any 
machines if you are feeling unwell. 
 
Cervarix contains sodium chloride. 
 
This medicinal product contains less than 1 mmol sodium (23 mg) per dose, i.e. essentially “sodium-
free”. 
 
 



46 

3. How Cervarix is given 
 
How the vaccine is given 
 
The doctor or nurse will give Cervarix as an injection into the muscle of the upper arm.  
 
How much is given 
Cervarix is intended for use from 9 years of age onwards. 
 
The total number of injections you will receive depends on your age at the time of the first injection. 
 
If you are between 9 and 14 years old 
 
You will receive 2 injections: 
 
First injection: at chosen date 
Second injection: given between 5 and 13 months after first injection 
 
If you are 15 years old or above 
 
You will receive 3 injections: 
 
First injection: at chosen date 
Second injection: 1 month after first injection 
Third injection: 6 months after first injection 
 
If necessary, the vaccination schedule can be more flexible. Please speak to your doctor for more 
information. 
 
When Cervarix is given for the first dose, it is recommended that Cervarix (and not another vaccine 
against HPV) be given for the complete vaccination course. 
 
Cervarix is not recommended for use below 9 years of age. 
 
The vaccine should never be given into a vein. 
 
If you miss a dose 
It is important that you follow the instructions of your doctor or nurse regarding return visits. If you 
forget to go back to your doctor at the scheduled time, ask your doctor for advice. 
 
If you do not finish the complete vaccination course (two or three injections depending on your age at 
vaccination), you may not get the best response and protection from the vaccination. 
 
 
4. Possible side effects 
 
Like all medicines, this vaccine can cause side effects, although not everybody gets them. 
 
Side effects that occurred during clinical trials with Cervarix were as follows: 
 
♦ Very common (side effects which may occur in more than 1 per 10 doses of vaccine): 

• pain or discomfort at the injection site 
• redness or swelling at the injection site 
• headache 
• aching muscles, muscle tenderness or weakness (not caused by exercise) 
• tiredness 

 



47 

♦ Common (side effects which may occur in less than 1 per 10 but more than 1 per 100 doses of 
vaccine):  
• gastrointestinal symptoms including nausea, vomiting, diarrhoea and abdominal pain 
• itching, red skin rash, hives (urticaria) 
• joint pain 
• fever (≥38°C) 

 
♦ Uncommon (side effects which may occur in less than 1 per 100 but more than 1 per 1,000 

doses of vaccine): 
• upper respiratory tract infection (infection of the nose, throat or trachea) 
• dizziness 
• other injection site reactions such as hard lump, tingling or numbness. 

 
Side effects that have been reported during marketed use of Cervarix include: 
 
• allergic reactions. These can be recognised by: 

itchy rash of the hands and feet, 
swelling of the eyes and face, 
difficulty in breathing or swallowing, 
sudden drop in blood pressure and loss of consciousness. 

These reactions will usually occur before leaving the doctor’s surgery.  However, if your child gets 
any of these symptoms you should contact a doctor urgently. 

• swollen glands in the neck, armpit or groin 
• fainting sometimes accompanied by shaking or stiffness. 
 
Reporting of side effects 
If you get any side effects , talk to your doctor or pharmacist. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system 
listed in Appendix V. By reporting side effects you can help provide more information on the safety of 
this medicine. 
 
 
5. How to store Cervarix 
 
Keep this vaccine out of the sight and reach of children. 
 
Do not use this vaccine after the expiry date which is stated on the carton. The expiry date refers to the 
last day of that month. 
 
Store in a refrigerator (2°C – 8°C). 
Do not freeze.  
Store in the original package in order to protect from light. 
 
After first opening, immediate use is recommended. If not used immediately, the vaccine should be 
stored in a refrigerator (2°C – 8°C). If not used within 6 hours it should be discarded. 
 
Do not throw away any medicines  via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help to protect the environment. 
 
 
6. Contents of the pack and other information 
 
What Cervarix contains 
 
- The active substances are: 
 



48 

Human Papillomavirus1 type 16 L1 protein2,3,4 20 micrograms 
Human Papillomavirus1 type 18 L1 protein2,3,4 20 micrograms 
 
1Human Papillomavirus = HPV 
 
2adjuvanted by AS04 containing: 
3-O-desacyl-4’- monophosphoryl lipid A (MPL)3 50 micrograms 
 
3adsorbed on aluminium hydroxide, hydrated (Al(OH)3)  0.5 milligrams Al3+ in total 
 
4L1 protein in the form of non-infectious virus-like particles (VLPs) produced by recombinant 
DNA technology using a Baculovirus expression system which uses Hi-5 Rix4446 cells derived 
from the insect Trichoplusia ni. 
 

- The other ingredients are sodium chloride (NaCl), sodium dihydrogen phosphate dihydrate 
(NaH2PO4.2 H2O) and water for injections. 

 
What Cervarix looks like and contents of the pack 
 
Suspension for injection. 
 
Cervarix is a turbid white suspension. 
 
Cervarix is available in 2 dose vials (1 ml) in packs of 1, 10 and 100. 
 
Not all pack sizes may be marketed. 
 
Marketing Authorisation Holder and Manufacturer 
 
GlaxoSmithKline Biologicals s.a. 
Rue de l'Institut 89 
B-1330 Rixensart, Belgium 
 
For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder: 
 
Belgique/België/Belgien 
GlaxoSmithKline Pharmaceuticals s.a./n.v. 
Tél/Tel: + 32 10 85 52 00 
 

Lietuva 
GlaxoSmithKline Lietuva UAB 
Tel: +370 5 264 90 00 
info.lt@gsk.com 

 
България 
ГлаксоСмитКлайн ЕООД 
Тел. + 359 2 953 10 34 
 

 
Luxembourg/Luxemburg 
GlaxoSmithKline Pharmaceuticals s.a./n.v. 
Tél/Tel: + 32 10 85 52 00 

Česká republika 
GlaxoSmithKline s.r.o. 
Tel: + 420 2 22 00 11 11 
cz.info@gsk.com 
 

Magyarország 
GlaxoSmithKline Kft. 
Tel.: + 36-1-2255300 
 

Danmark 
GlaxoSmithKline Pharma A/S 
Tlf: + 45 36 35 91 00 
dk-info@gsk.com 
 

Malta 
GlaxoSmithKline (Malta) Ltd 
Tel: + 356 21 238131 
 

Deutschland 
GlaxoSmithKline GmbH & Co. KG 

Nederland 
GlaxoSmithKline BV 



49 

Tel: + 49 (0)89 360448701 
produkt.info@gsk.com 
 

Tel: + 31 (0)30 69 38 100 
nlinfo@gsk.com 

Eesti 
GlaxoSmithKline Eesti OÜ  
Tel: +372 667 6900 
estonia@gsk.com 
 

Norge 
GlaxoSmithKline AS 
Tlf: + 47 22 70 20 00 
 

Ελλάδα 
GlaxoSmithKline A.E.B.E 
Tηλ: + 30 210 68 82 100 
 

Österreich 
GlaxoSmithKline Pharma GmbH 
Tel: + 43 (0)1 97075 0 
at.info@gsk.com 
 

España 
GlaxoSmithKline, S.A. 
Tel: + 34 902 202 700 
es-ci@gsk.com  
 

Polska 
GSK Services Sp. z o.o. 
Tel.: + 48 (22) 576 9000 
 

France 
Laboratoire GlaxoSmithKline 
Tél: + 33 (0) 1 39 17 84 44 
diam@gsk.com 
 
 
Hrvatska 
GlaxoSmithKline d.o.o. 
Tel.: + 385 (0)1 6051999 
 

Portugal 
GlaxoSmithKline - Produtos Farmacêuticos, 
Lda. 
Tel: + 351 21 412 95 00 
FI.PT@gsk.com 
 
România 
GlaxoSmithKline (GSK) SRL 
Tel: +40 (0)21 3028 208 
 

Ireland 
GlaxoSmithKline (Ireland) Ltd 
Tel: + 353 (0)1 495 5000 
 

Slovenija 
GlaxoSmithKline d.o.o. 
Tel: + 386 (0) 1 280 25 00 
medical.x.si@gsk.com 
 

Ísland 
Vistor hf.  
Sími: +354 535 7000 

Slovenská republika 
GlaxoSmithKline Slovakia s.r.o. 
Tel.: + 421 (0)2 48 26 11 11 
recepcia.sk@gsk.com  
 

Italia 
GlaxoSmithKline S.p.A. 
Tel:+ 39 (0)45 9218 111 
 
 

Suomi/Finland 
GlaxoSmithKline Oy 
Puh/Tel: + 358 10 30 30 30 
Finland.tuoteinfo@gsk.com 
 

Κύπρος 
GlaxoSmithKline (Cyprus) Ltd 
Τηλ: + 357 22 39 70 00 
gskcyprus@gsk.com 
 

Sverige 
GlaxoSmithKline AB 
Tel: + 46 (0)8 638 93 00 
info.produkt@gsk.com  

Latvija 
GlaxoSmithKline Latvia SIA 
Tel: + 371 67312687 
lv-epasts@gsk.com 

United Kingdom 
GlaxoSmithKline UK 
Tel: +44 (0)800 221 441 
customercontactuk@gsk.com 
 

  
This leaflet was last revised in (MM/YYYY) 
 
Other sources of information 

mailto:gskcyprus@gsk.com
mailto:gskcyprus@gsk.com


50 

 
Detailed information on this medicine is available on the European Medicines Agency web site: 
http://www.ema.europa.eu. 
 
------------------------------------------------------------------------------------------------------------------------- 
 
The following information is intended for healthcare professionals only: 
 
Cervarix should be administered as soon as possible after being removed from the refrigerator. 
However, stability has been demonstrated when stored outside the refrigerator for up to 3 days at 
temperatures between 8°C and 25°C or for up to 1 day at temperatures between 25°C and 37°C. If not 
used at the end of this period the vaccine should be discarded. 
 
A fine white deposit with a clear colourless supernatant may be observed upon storage of the vial. This 
does not constitute a sign of deterioration. 
 
The content of the vial should be inspected visually both before and after shaking for any foreign 
particulate matter and/or abnormal physical appearance prior to administration.  
In the event of either being observed, discard the vaccine. 
 
The vaccine should be well shaken before use. 
 
When using a multidose vial, each 0.5 ml dose should be withdrawn using a sterile needle and syringe; 
precautions should be taken to avoid contamination of the contents. 
 
Any unused medicinal product or waste material should be disposed of in accordance with local 
requirements. 



51 

 
Package leaflet: Information for the user 

 
Cervarix suspension for injection in pre-filled syringe 

Human Papillomavirus vaccine [Types 16, 18] (Recombinant, adjuvanted, adsorbed) 
 

Read all of this leaflet carefully before you start receiving this vaccine because it contains 
important information for you. 
- Keep this leaflet. You may need to read it again. 
- If you have any further questions, ask your doctor or pharmacist. 
- This medicine has been prescribed for you only. Do not pass it on to others.  
- If you get any side effects, talk to your doctor or pharmacist. This includes any possible side 

effects not listed in this leaflet. See section 4. 
 
What is in this leaflet:  
1. What Cervarix is and what it is used for 
2. What you need to know before you receive Cervarix 
3. How Cervarix is given 
4. Possible side effects 
5. How to store Cervarix 
6. Contents of the pack and other information 
 
 
1. What Cervarix is and what it is used for 
 
Cervarix is a vaccine intended to protect from the age of 9 years against the diseases caused by 
infection with Human Papillomaviruses (HPV). 
 
These diseases include: 
- cervical cancer (cancer of the cervix i.e. lower part of the uterus or womb) and anal cancer,  
- precancerous cervical, vulvar, vaginal and anal lesions (changes in genital or anal cells that have a 

risk of turning into cancer). 
 
The Human Papillomavirus (HPV) types contained in the vaccine (HPV types 16 and 18) are 
responsible for approximately 70% of cervical cancers, 90% of anal cancers, 70% of HPV-related pre-
cancerous lesions of the vulva and vagina and 78% of HPV-related pre-cancerous lesions of the anus. 
Other HPV types can also cause ano-genital cancers. Cervarix does not protect against all HPV types. 
 
When a female or a male individual is vaccinated with Cervarix, the immune system (the body’s 
natural defence system) will make antibodies against HPV types 16 and 18.  
 
Cervarix is not infectious and so, it cannot cause HPV related diseases. 
 
Cervarix is not used to treat HPV related diseases already present at the time of vaccination. 
 
Cervarix should be used in accordance with official guidelines. 
 
 
2. What you need to know before you receive Cervarix 
 
Cervarix should not be given: 
 
• if you are allergic to any of the active substances or any of the other ingredients of this vaccine 

(listed in section 6). Signs of an allergic reaction may include itchy skin rash, shortness of 
breath and swelling of the face or tongue. 
 

 



52 

Warnings and precautions 
Talk to your doctor or pharmacist before you are given Cervarix 
• if you have a bleeding problem or bruise easily. 
• if you have any disease which reduces your resistance to infection such as HIV infection. 
• if you have a severe infection with a high temperature. It might be necessary to postpone the 

vaccination until recovery. A minor infection such as a cold should not be a problem, but talk to 
the doctor first. 

 
Fainting can occur (mostly in adolescents) following, or even before, any needle injection. Therefore 
tell the doctor or nurse if you or your child fainted with a previous injection. 
 
As with all vaccines, Cervarix may not fully protect all people who are vaccinated. 
 
Cervarix does not protect people from diseases caused by infection with HPV types 16 or 18 if they 
are already infected with Human Papillomavirus type 16 or 18 at the time of vaccination. 
 
Although vaccination may protect you against cervical cancer, it is not a substitute for regular cervical 
screening. You should continue to follow your doctor’s advice on cervical smear/Pap test (test to 
screen for changes in cells of the cervix caused by an HPV infection) and preventative and protective 
measures. 
 
As Cervarix will not protect against all types of Human Papillomavirus, appropriate precautions 
against exposure to HPV and sexually transmitted diseases should continue to be used. 
 
Cervarix will not protect against other diseases that are not caused by Human Papillomavirus. 
 
Other medicines and Cervarix 
Cervarix can be given with a combined booster vaccine containing diphtheria (d), tetanus (T) and 
pertussis [acellular] (pa) with or without inactivated poliomyelitis (IPV), (dTpa, dTpa -IPV vaccines), 
with a combined hepatitis A and hepatitis B vaccine (Twinrix) or a hepatitis B vaccine (Engerix B), or 
with a meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate vaccine (MenACWY-TT), 
at a separate injection site (another part of your body, e.g. the other arm) during the same visit. 
 
Cervarix may not have an optimal effect if used with medicines that suppress the immune system. 
 
In clinical trials, oral contraceptives (e.g. the pill) did not reduce the protection obtained by Cervarix. 
 
Tell your doctor if you are taking, have recently taken, might take any other medicines, or have 
recently received any other vaccine. 
 
Pregnancy, breast-feeding and fertility 
If you are pregnant, if pregnancy occurs during the course of vaccination or if you are trying to 
become pregnant it is recommended to postpone or interrupt vaccination until after completion of the 
pregnancy. 
 
If you are pregnant or breast-feeding, think that you may be pregnant or are planning to have a baby, 
ask your doctor for advice before you are given this vaccine. 
 
Driving and using machines 
Cervarix is not likely to affect your ability to drive or use machines. However, do not drive or use any 
machines if you are feeling unwell. 
 
Cervarix contains sodium chloride. 
 
This medicinal product contains less than 1 mmol sodium (23 mg) per dose, i.e. essentially “sodium-
free”. 
 



53 

 
3. How Cervarix is given 
 
How the vaccine is given 
The doctor or nurse will give Cervarix as an injection into the muscle of the upper arm.  
 
How much is given 
Cervarix is intended for use from 9 years of age onwards.  
 
The total number of injections you will receive depends on your age at the time of the first injection. 
 
If you are between 9 and 14 years old 
 
You will receive 2 injections: 
 
First injection: at chosen date 
Second injection: given between 5 and 13 months after first injection 
 
If you are 15 years old or above 
 
You will receive 3 injections: 
 
First injection: at chosen date 
Second injection: 1 month after first injection 
Third injection: 6 months after first injection 
 
If necessary, the vaccination schedule can be more flexible. Please speak to your doctor for more 
information. 
 
When Cervarix is given for the first dose, it is recommended that Cervarix (and not another vaccine 
against HPV) be given for the complete vaccination course. 
 
The vaccine should never be given into a vein. 
 
Cervarix is not recommended for use below 9 years of age. 
 
If you miss a dose 
It is important that you follow the instructions of your doctor or nurse regarding return visits. If you 
forget to go back to your doctor at the scheduled time, ask your doctor for advice. 
 
If you do not finish the complete vaccination course (two or three injections depending on your age at 
vaccination), you may not get the best response and protection from the vaccination. 
 
 
4. Possible side effects 
 
Like all medicines, this vaccine can cause side effects, although not everybody gets them. 
 
Side effects that occurred during clinical trials with Cervarix were as follows: 
 
♦ Very common (side effects which may occur in more than 1 per 10 doses of vaccine): 

• pain or discomfort at the injection site 
• redness or swelling at the injection site 
• headache 
• aching muscles, muscle tenderness or weakness (not caused by exercise) 
• tiredness 

 



54 

♦ Common (side effects which may occur in less than 1 per 10 but more than 1 per 100 doses of 
vaccine):  
• gastrointestinal symptoms including nausea, vomiting, diarrhoea and abdominal pain 
• itching, red skin rash, hives (urticaria) 
• joint pain 
• fever (≥38°C) 

 
♦ Uncommon (side effects which may occur in less than 1 per 100 but more than 1 per 1,000 

doses of vaccine): 
• upper respiratory tract infection (infection of the nose, throat or trachea) 
• dizziness 
• other injection site reactions such as hard lump, tingling or numbness. 

 
Side effects that have been reported during marketed use of Cervarix include: 
 
• allergic reactions. These can be recognised by: 

itchy rash of the hands and feet, 
swelling of the eyes and face, 
difficulty in breathing or swallowing, 
sudden drop in blood pressure and loss of consciousness. 

These reactions will usually occur before leaving the doctor’s surgery.  However, if your child gets 
any of these symptoms you should contact a doctor urgently. 

• swollen glands in the neck, armpit or groin 
• fainting sometimes accompanied by shaking or stiffness. 
 
Reporting of side effects 
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system 
listed in Appendix V. By reporting side effects you can help provide more information on the safety of 
this medicine. 
 
 
5. How to store Cervarix 
 
Keep this vaccine out of the sight and reach of children. 
 
Do not use this vaccine after the expiry date which is stated on the carton. The expiry date refers to the 
last day of that month. 
 
Store in a refrigerator (2°C – 8°C). 
Do not freeze.  
Store in the original package in order to protect from light. 
 
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help to protect the environment. 
 
 
6. Contents of the pack and other information 
 
What Cervarix contains 
 
- The active substances are: 
 

Human Papillomavirus1 type 16 L1 protein2,3,4 20 micrograms 
Human Papillomavirus1 type 18 L1 protein2,3,4 20 micrograms 
 

http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc
http://www.ema.europa.eu/docs/en_GB/document_library/Template_or_form/2013/03/WC500139752.doc


55 

1Human Papillomavirus = HPV 
 
2adjuvanted by AS04 containing: 
3-O-desacyl-4’- monophosphoryl lipid A (MPL)3 50 micrograms 
 
3adsorbed on aluminium hydroxide, hydrated (Al(OH)3)  0.5 milligrams Al3+ in total 
 
4L1 protein in the form of non-infectious virus-like particles (VLPs) produced by recombinant 
DNA technology using a Baculovirus expression system which uses Hi-5 Rix4446 cells derived 
from the insect Trichoplusia ni. 
 

- The other ingredients are sodium chloride (NaCl), sodium dihydrogen phosphate dihydrate 
(NaH2PO4.2 H2O) and water for injections. 

 
What Cervarix looks like and contents of the pack 
 
Suspension for injection in pre-filled syringe. 
 
Cervarix is a turbid white suspension. 
 
Cervarix is available in pre-filled syringes (0,5 ml) with or without needles in packs of 1 and 10. 
 
Not all pack sizes may be marketed. 
 
Marketing Authorisation Holder and Manufacturer 
 
GlaxoSmithKline Biologicals s.a. 
Rue de l'Institut 89 
B-1330 Rixensart, Belgium 
 
For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder: 
 
Belgique/België/Belgien 
GlaxoSmithKline Pharmaceuticals s.a./n.v. 
Tél/Tel: + 32 10 85 52 00 
 

Lietuva 
GlaxoSmithKline Lietuva UAB 
Tel: +370 5 264 90 00 
info.lt@gsk.com 

 
България 
ГлаксоСмитКлайн ЕООД 
Тел. + 359 2 953 10 34 
 

 
Luxembourg/Luxemburg 
GlaxoSmithKline Pharmaceuticals s.a./n.v. 
Tél/Tel: + 32 10 85 52 00 

Česká republika 
GlaxoSmithKline s.r.o. 
Tel: + 420 2 22 00 11 11 
cz.info@gsk.com 
 

Magyarország 
GlaxoSmithKline Kft. 
Tel.: + 36-1-2255300 
 

Danmark 
GlaxoSmithKline Pharma A/S 
Tlf: + 45 36 35 91 00 
dk-info@gsk.com 
 

Malta 
GlaxoSmithKline (Malta) Ltd 
Tel: + 356 21 238131 
 

Deutschland 
GlaxoSmithKline GmbH & Co. KG 
Tel: + 49 (0)89 360448701 
produkt.info@gsk.com 
 

Nederland 
GlaxoSmithKline BV 
Tel: + 31 (0)30 69 38 100 
nlinfo@gsk.com 



56 

Eesti 
GlaxoSmithKline Eesti OÜ  
Tel: +372 667 6900 
estonia@gsk.com 
 

Norge 
GlaxoSmithKline AS 
Tlf: + 47 22 70 20 00 
 

Ελλάδα 
GlaxoSmithKline A.E.B.E 
Tηλ: + 30 210 68 82 100 
 

Österreich 
GlaxoSmithKline Pharma GmbH 
Tel: + 43 (0)1 97075 0 
at.info@gsk.com 

 
España 
GlaxoSmithKline, S.A. 
Tel: + 34 902 202 700 
es-ci@gsk.com  
 

 
Polska 
GSK Services Sp. z o.o. 
Tel.: + 48 (22) 576 9000 
 

France 
Laboratoire GlaxoSmithKline 
Tél: + 33 (0) 1 39 17 84 44 
diam@gsk.com 
 
Hrvatska 
GlaxoSmithKline d.o.o. 
Tel.: + 385 (0)1 6051999 
 

Portugal 
GlaxoSmithKline - Produtos Farmacêuticos, 
Lda. 
Tel: + 351 21 412 95 00 
FI.PT@gsk.com 
 
România 
GlaxoSmithKline (GSK) SRL 
Tel: +40 (0)21 3028 208 
 

Ireland 
GlaxoSmithKline (Ireland) Ltd 
Tel: + 353 (0)1 495 5000 
 

Slovenija 
GlaxoSmithKline d.o.o. 
Tel: + 386 (0) 1 280 25 00 
medical.x.si@gsk.com 
 

Ísland 
Vistor hf.  
Sími: +354 535 7000 
 

Slovenská republika 
GlaxoSmithKline Slovakia s.r.o. 
Tel.: + 421 (0)2 48 26 11 11 
recepcia.sk@gsk.com  
 

Italia 
GlaxoSmithKline S.p.A. 
Tel:+ 39 (0)45 9218 111 
 
 

Suomi/Finland 
GlaxoSmithKline Oy 
Puh/Tel: + 358 10 30 30 30 
Finland.tuoteinfo@gsk.com 
 

Κύπρος 
GlaxoSmithKline (Cyprus) Ltd 
Τηλ: + 357 22 39 70 00 
gskcyprus@gsk.com 
 

Sverige 
GlaxoSmithKline AB 
Tel: + 46 (0)8 638 93 00 
info.produkt@gsk.com  

Latvija 
GlaxoSmithKline Latvia SIA 
Tel: + 371 67312687 
lv-epasts@gsk.com 

United Kingdom 
GlaxoSmithKline UK 
Tel: +44 (0)800 221 441 
customercontactuk@gsk.com 
 

  
This leaflet was last revised in (MM/YYYY) 
 
Other sources of information 
 
Detailed information on this medicine is available on the European Medicines Agency web site: 
http://www.ema.europa.eu. 

mailto:gskcyprus@gsk.com
mailto:gskcyprus@gsk.com


57 

 
------------------------------------------------------------------------------------------------------------------------- 
 
The following information is intended for healthcare professionals only: 
 
Cervarix should be administered as soon as possible after being removed from the refrigerator. 
However, stability has been demonstrated when stored outside the refrigerator for up to 3 days at 
temperatures between 8°C and 25°C or for up to 1 day at temperatures between 25°C and 37°C. If not 
used at the end of this period the vaccine should be discarded. 
 
A fine white deposit with a clear colourless supernatant may be observed upon storage of the syringe. 
This does not constitute a sign of deterioration. 
 
The content of the syringe should be inspected visually both before and after shaking for any foreign 
particulate matter and/or abnormal physical appearance prior to administration.  
In the event of either being observed, discard the vaccine. 
 
The vaccine should be well shaken before use. 
 
Instructions for administration of the vaccine presented in pre-filled syringe 
 
 
1. Holding the syringe barrel in one hand  
(avoid holding the syringe plunger),  
unscrew the syringe cap by twisting it anticlockwise. 
 
 
 
 
 
 
 
2. To attach the needle to the syringe,  
twist the needle clockwise into the syringe  
until you feel it lock.  
 
 
3. Remove the needle protector, which on  
occasion can be a little stiff. 
 
 
4. Administer the vaccine. 
 
 
 
 
Any unused medicinal product or waste material should be disposed of in accordance with local 
requirements. 
 
 
 

Syringe plunger 
Syringe barrel Syringe cap 

Needle protector 


	SUMMARY OF PRODUCT CHARACTERISTICS
	A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE
	B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE
	C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION
	D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
	A. LABELLING
	B. PACKAGE LEAFLET